



Australian Government

Department of Health and Ageing

**SCHEDULE OF PHARMACEUTICAL BENEFITS
FOR DENTAL PRACTITIONERS**

This Schedule is also available on the internet at
www.pbs.gov.au

**EFFECTIVE 1 September 2011 -
30 September 2011
(ALL PREVIOUS EDITIONS CANCELLED)**

© Commonwealth of Australia 2011

ISSN 1037-3667

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

This Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These arrangements operate under the *National Health Act 1953*. However, at the time of printing, the relevant legislation giving authority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment for the supply of pharmaceutical benefits. The legislation is available from the Federal Register of Legislative Instruments website at <http://www.frl.gov.au>.

The information is not intended to give or replace any legal, medical, dental or optometrical advice. This document is not a legal document and does not constitute legal advice. Neither the information nor this document can be relied upon without first seeking and obtaining independent legal, medical, dental or optometrical advice beforehand. To the extent permitted by law, the Commonwealth of Australia will not be held responsible, nor accept any liability (whether arising out of negligence or otherwise), for any injury, damages, costs, expenses and losses suffered or incurred by a person where such a person has relied on this document or used the information in it as legal, medical, dental or optometrical advice.

CONTENTS

| | |
|--|----|
| SUMMARY OF CHANGES | 4 |
| Deletions..... | 4 |
| Deletions – Items..... | 4 |
| Deletions – Brands..... | 4 |
| Section 1 – Explanatory Notes..... | 5 |
| Introduction..... | 5 |
| 1. The Schedule — Where to Find What | 5 |
| Section 1 | 5 |
| Section 2 | 5 |
| 2. Prescribing Medicines — Information for Dentists..... | 5 |
| Eligible prescribers..... | 5 |
| PBS prescription forms | 5 |
| Preparing general prescriptions..... | 6 |
| Restrictions | 6 |
| Maximum quantities..... | 6 |
| Urgent cases | 7 |
| 3. Patient Charges..... | 7 |
| Type of patient | 7 |
| What patients pay | 7 |
| 4. RPBS Dental Prescribing..... | 8 |
| Addresses — Medicare Australia..... | 9 |
| THERAPEUTIC INDEX..... | 13 |
| Section 2 | 16 |
| SYMBOLS USED IN THE SCHEDULE | 17 |
| GENERIC/PROPRIETARY INDEX | 46 |

PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 September 2011. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

SUMMARY OF CHANGES

Deletions

Deletions – Items

- 5217N **Sulindac**, Tablet 100 mg (*Aclin*)
5218P **Sulindac**, Tablet 200 mg (*Aclin 200*)
3389J **Trimethoprim with Sulfamethoxazole**, Tablet 80 mg-400 mg (*Resprim*)

Deletions – Brands

- 3321T *Vibramycin, PF* – **Doxycycline**, Tablet 100 mg (as hydrochloride)

Section 1 – Explanatory Notes

Introduction

These Explanatory Notes are provided to help dentists work within the Australian Government's Pharmaceutical Benefits Scheme (PBS).

The PBS is a system of subsidising the cost of most prescription medicines. The subsidies are available to all Australian residents and eligible foreign visitors, i.e., people from countries which have Reciprocal Health Care Agreements with Australia. These countries are the United Kingdom, Ireland, New Zealand, Malta, Italy, Sweden, the Netherlands, Finland, Norway and Belgium.

The aim of the PBS, which has been in operation since 1948, is to provide reliable and affordable access to a wide range of necessary medicines.

The Schedule of Pharmaceutical Benefits – referred to throughout as the 'Schedule' – lists all of the medicines available under the PBS, and explains how they can be used in order to be subsidised.

The Schedule is produced monthly by the Australian Department of Health and Ageing (effective on the first day of each month).

It is vital therefore that dentists remain up to date with information on which medicines are included in or excluded from the Schedule, whether restrictions apply to the medicines, and how much patients should pay. Queries relating to the PBS can be made to the Pharmaceutical Branch in the State offices of Medicare Australia (telephone 132 290 Mondays to Fridays, during business hours). Queries relating to the Repatriation Pharmaceutical Benefits Scheme (RPBS) can be made to the State offices of the Department of Veterans' Affairs (DVA) (telephone 1800 552 580).

1. The Schedule — Where to Find What

The Schedule of Pharmaceutical Benefits is divided into sections. At the start of the Schedule, immediately after the table of contents, is a summary of any changes to listed items.

The last pages of the Schedule provide a generic/proprietary index of PBS and RPBS ready-prepared items.

Section 1

Section 1 is what you are reading, the Explanatory Notes. It outlines the correct way to prescribe pharmaceutical benefits, patient charges and who qualifies for concessions. This is followed by a list of Medicare Australia contacts and addresses, then an index of manufacturers' codes.

Section 2

This section lists ready-prepared items, and includes the form, manner of administration, brand and brand equivalents that may be prescribed, and the maximum quantity for each item.

Any medicines that have restrictions on how they can be prescribed are printed in ***bold italics***. Items appearing in more than one therapeutic group are cross-referenced.

Section 2 SYMBOLS USED IN THE SCHEDULE explains symbols used throughout the Schedule.

The use of 'NOTE' in this section is used to clarify how some pharmaceutical benefits should be prescribed.

The use of 'CAUTION' is to warn of known adverse reactions from, or precautions to be taken with, a particular pharmaceutical benefit. (The absence of a cautionary note does not imply reactions may not happen.)

2. Prescribing Medicines — Information for Dentists

Eligible prescribers

Pharmaceutical benefits can only be prescribed by dentists who are approved to work within the PBS.

PBS prescription forms

Standard PBS prescription forms are available from Medicare Australia for prescribing pharmaceutical benefits.

- *Personalised forms* – have the dentist's name, qualifications, practice address/es, telephone number and prescriber number.
- *Non-personalised (blank) forms* – are distributed for emergency supply only. Both forms for dentists are supplied free of charge.

Ordering forms

Dentists are asked not to over order. Getting the right amount of forms helps to reduce the cost to taxpayers and helps to reduce paper wastage. Also, the pads may deteriorate if stored over time.

Order forms for standard PBS prescription forms are available from Medicare Australia stationery officers. Contact details are listed in the front of the Schedule.

Orders for PBS prescription stationery will only be accepted by application in writing and through the channels mentioned above.

Preparing general prescriptions

Do's and don't's

A PBS prescription is only valid when it is written by an approved dentist for dental treatment only.

The prescription must be for the treatment of the person named on the PBS prescription. A PBS prescription may only be written for the treatment of one person.

A dentist cannot write more than one PBS prescription for the same pharmaceutical benefit for the same person on the same day.

Up to **three** pharmaceutical benefit items may be included on a single PBS prescription form, but pharmaceutical benefits and non-pharmaceutical benefits should not be listed together on the one PBS prescription form.

If an item has a particular manner of administration it may not, as a pharmaceutical benefit, be administered in any other way, e.g., an ophthalmic preparation may not be prescribed for topical use.

If an item is restricted, but the patient is not suffering from one of the specified conditions, it cannot be prescribed as a pharmaceutical benefit. The dentist should write the prescription either on a private prescription or on a standard prescription with 'PBS/RPBS' clearly struck out. It should also be endorsed 'non-PBS'.

A dentist cannot prescribe a narcotic drug for him/herself. In some States and Territories the prescribing of drugs of addiction by dentists is not permitted.

Dentists are issued with individual PBS prescription pads by Medicare Australia for their own use – these pads should not be used by other dentists, as this can cause confusion through incorrect pharmacy records.

Dentists are required to include their prescriber numbers on non-personalised PBS prescriptions.

The following admixtures are not pharmaceutical benefits:

- the admixture of two or more ready-prepared items listed in the Schedule; or
- the admixture of a non-pharmaceutical benefit item with a pharmaceutical benefit item.

Writing the PBS prescription

The following rules apply for writing PBS prescriptions:

- they must be written in indelible form (i.e., ink or ball-point pen) in the dentist's own handwriting (exceptions must be approved by Medicare Australia's Chief Executive Officer) either on the standard PBS prescription, or on paper approximately 18 cm x 12 cm, or they can be generated by computer on a form approved by Medicare Australia. For patient safety reasons, both the original and the duplicate must be legible;
- they must record the dentist's name, address and prescriber number, the patient's name, address and entitlement status (i.e. whether they are a 'concessional' or 'general' patient), and whether the prescription is under the PBS or RPBS;
- they should completely identify the pharmaceutical benefit by detailing the item, dose, form, strength, quantity and instructions for use;
- they should indicate where brand substitution is not permitted. PBS prescriptions must not be prepared using a computer prescribing program that contains a default which would result in all prescriptions being indicated as Brand Substitution Not Permitted;
- where 'solvent required' is included after the form, the volume and number of ampoules must be specified; and
- they must be signed by the dentist and dated. Forward or back dating is not permitted.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a dental practitioner providing dental services within a participating public hospital, may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

Restrictions

Pharmaceutical benefits listed in this Schedule fall into two broad categories:

Unrestricted benefits – which have no restrictions on their therapeutic uses; and

Restricted benefits – which can only be prescribed for specific therapeutic uses (they are noted as **restricted benefit**).

Maximum quantities

The maximum quantities allowed for PBS items are recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). Dentists cannot prescribe repeats.

PBS prescriptions can be for any quantity up to the maximum. It is not necessary to prescribe the maximum quantity if a lesser quantity is sufficient for the patient's needs. Please clearly indicate the number of tablets, capsules, etc. required, and **do not use** abbreviations such as 'Max. Qty', or 'M.Q.'

Urgent cases

In urgent cases and where State/Territory law allows, a dentist may telephone a pharmacist and ask that a PBS prescription be supplied. He/she must then forward the written PBS prescription and duplicate to the pharmacist within **seven days of the date of supply**.

3. Patient Charges

Type of patient

There are two types of PBS beneficiaries – general patients and concessional patients. General patients hold a Medicare card. Concessional patients hold a Medicare card and one of the following cards from Centrelink or the Department of Veterans' Affairs (DVA):

- Pensioner Concession Card
- Commonwealth Seniors Health Card
- Health Care Card
- Repatriation Health Card For All Conditions (gold) – concessional patients under RPBS
- Repatriation Health Card For Specific Conditions (white) – only regarded as concessional patients for RPBS prescriptions unless they hold a separate entitlement from Centrelink, otherwise they are general patients
- Repatriation Pharmaceutical Benefits Card (orange) – concessional patients under RPBS
- Safety Net Concession Card or Safety Net Entitlement Card are also issued by Medicare Australia.

Under the Reciprocal Health Care Agreements (RHCA), visitors from participating countries (see the introduction of this section for the list of countries) are treated as general patients – they do not have concessional entitlements. To receive pharmaceutical benefits, these visitors may need to present a temporary Medicare card or their passport.

What patients pay

Patient contribution

Under the PBS, the maximum cost for a pharmaceutical benefit item at a pharmacy is \$34.20 for general patients and \$5.60 for concessional patients (except where a brand premium applies).

Patients who have a Safety Net Entitlement Card receive PBS items for free, except where a brand premium applies.

The contribution rate for general patients as outpatients at public hospitals throughout Australia is \$27.40.

The exception is Queensland and hospitals participating in the pharmaceutical reforms where they pay the safety net value of an item when it is listed in the Schedule, or up to \$34.20 for items not listed in the Schedule. The public hospital pharmaceutical reforms enable participating public hospitals to prescribe and supply pharmaceutical medication from the PBS to outpatients and patients upon discharge.

The contribution rate for concessional patients in all public hospitals is \$5.60.

The supply of a pharmaceutical benefit or a Repatriation pharmaceutical benefit to a patient is a GST-free supply. Goods and services tax must not be included in the price charged to a patient for the supply of a benefit under the PBS or RPBS.

It is the patient's responsibility to meet any charge lawfully demanded by an approved pharmacist, otherwise supply may be refused.

The patient contribution rates are usually adjusted on 1 January each year in line with inflation.

Patient contributions for early supply of some PBS medicines

Prescriptions for some pharmaceutical benefits are not eligible for Safety Net benefits if resupplied within 20 days of a previous supply of the same pharmaceutical benefit for the same person under the PBS or the RPBS. (This is known as the 'Safety Net 20 day rule' which came into effect on 1 January 2006.)

Where a prescription is subject to the Safety Net 20 day rule, exclusion from Safety Net benefits has the following effects:

- the patient contribution does not count towards the Safety Net
- after the Safety Net threshold is reached, the usual patient payment amount for the corresponding entitlement level (not the Safety Net amount) applies.

There are no pharmaceutical benefits listed for prescribing by dentists that are subject to the Safety Net 20 day rule.

Brand premiums

Under the brand premium arrangements, Commonwealth reimbursement to pharmacists is based on the lowest-priced brand. Patients pay the difference for higher-priced brands, on top of their usual patient contribution.

The Schedule's brand premiums apply to maximum quantities. When a quantity is less than the maximum, the premium will be a fraction of the maximum quantity, using standard pricing rules.

Solvents

Where a solvent is prescribed as part of a pharmaceutical benefit, only one patient contribution is charged.

4. RPBS Dental Prescribing

Under Department of Veterans' Affairs (DVA) arrangements, financial responsibility for pharmaceutical benefits prescribed by a Local Dental Officer (LDO) is limited to the treatment to which holders of the following cards are entitled:

- a Gold Repatriation Health Card For All Conditions; or
- a White Repatriation Health Card For Specific Conditions; or
- an Orange Repatriation Pharmaceutical Benefits Card.

Where possible the LDO shall prescribe in accordance with the provisions governing dental prescribing under the PBS.

Prescriptions for PBS Dental Schedule items for Gold, White and Orange Card holders are to be dispensed at the PBS concessional rate. The card holder is required to meet the cost of any applicable brand premium.

When a non-PBS Dental Schedule item is prescribed for an eligible card holder, the LDO's private prescription form should be used. The dispensing pharmacist may charge the patient the full cost of the prescription. The patient may claim a refund for the full cost of a non-Schedule item from DVA if an itemised receipt (not a cash register receipt) and a copy of the prescription are provided.

Addresses — Medicare Australia

Medicare Australia has responsibility for the operational aspects of the Pharmaceutical Benefits Scheme (PBS). This responsibility covers the processing of pharmaceutical benefit and safety net claims, authority applications and supply of PBS stationery used by medical practitioners, participating dental practitioners and approved pharmacists.

Procedures for ordering prescription forms are set out in Introduction of this Schedule .

New South Wales and Australian Capital Territory

Pharmaceutical Benefits Branch
130 George Street
Parramatta NSW 2150

General and IME enquiries — Tel: 132 290

Orange Service Centre
189 Anson Street
Orange NSW 2800

General and IME enquiries — Tel: 132 290

Victoria

Pharmaceutical Branch
Level 10
595 Collins Street
Melbourne Vic 3000

General and IME enquiries — Tel: 132 290

Queensland

Pharmaceutical Services Branch
143 Turbot Street
Brisbane Qld 4000

General and IME enquiries — Tel: 132 290

South Australia and Northern Territory

Pharmaceutical Services Branch
209 Greenhill Road
Eastwood SA 5063

General and IME enquiries — Tel: 132 290

Western Australia

Pharmaceutical Benefits Branch
Level 5, Work Distribution Centre,
(Reception on Level 4)
130 Stirling Street
Northbridge WA 6003

General and IME enquiries — Tel: 132 290

Tasmania

Pharmaceutical Branch
199 Collins Street
Hobart Tas 7000

General and IME enquiries — Tel: 132 290

National Program Management

Pharmaceutical Benefits Branch
Medicare Australia
134 Reed Street
Tuggeranong ACT 2900

Telephone — (02) 6124 6333

Website — www.medicareaustralia.gov.au Email — pbs@medicareaustralia.gov.au

Index of Manufacturers' Codes

| <i>Code</i> | <i>Manufacturer</i> | <i>Code</i> | <i>Manufacturer</i> |
|-------------|--|-------------|--|
| AB | Abbott Australasia Pty Ltd Sir Joseph Banks Corporate Park 32-34 Lord Street Botany NSW 2019 Tel: (02) 9384 9700 Fax: (02) 9384 9800 | BX | Baxter Healthcare Pty Limited 1 Baxter Drive Old Toongabbie NSW 2146 Tel: (02) 9848 1111 Fax: (02) 9848 1123 |
| AE | AFT Pharmaceuticals Pty Ltd Level 1, 296 Burns Bay Road Lane Cove NSW 2066 Tel: 1800 097 639 Fax: 1800 097 810 | CH | Chem mart Pty Limited Level 7, 5 Queens Road Melbourne Vic 3004 Tel: (03) 9918 2500 Fax: (03) 9918 2006 |
| AF | Alphapharm Pty Limited Chase Building 2 Wentworth Park Road Glebe NSW 2037 Tel: (02) 9298 3999 Fax: (02) 9566 4686 | CO | Chemists' Own Pty Ltd A member of Aspen Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2802 |
| AL | Alphapharm Medical A Division of Alphapharm Pty Limited Chase Building 2 Wentworth Park Road Glebe NSW 2037 Tel: (02) 9298 3999 Fax: (02) 9566 4686 | CR | Pharmacor Limited 5/36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475 |
| AS | Aspen Pharmacare Australia Pty Ltd First Floor, 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540 | CS | CSL Limited 45 Poplar Road Parkville Vic 3052 Tel: (03) 9389 1911 Fax: (03) 9388 2351 |
| AV | Aventis Pharma Division of Sanofi-Aventis Australia Pty Limited Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000 | FK | Invida Australia Pty Ltd Level 8, 67 Albert Avenue Chatswood NSW 2067 Tel: (02) 9080 7200 Fax: (02) 9080 7201 |
| BF | Bellwether Pharma Ltd Suite 1, Level 1 1175 Toorak Road Camberwell Vic 3124 Tel: (03) 9809 7900 Fax: (03) 9809 7999 | FM | Fawns and McAllan Pty Ltd A member of Aspen Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2802 |
| BQ | Bristol-Myers Squibb Pharmaceuticals A Division of Bristol-Myers Squibb Australia Pty Ltd 556 Princes Highway Noble Park Vic 3174 Tel: (03) 9213 4000 Fax: (03) 9701 1518 | FZ | Pfizer Established Products Division of Pfizer Australia Pty Ltd 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9850 3111 |
| BR | B. Braun Australia Pty Ltd Norwest Business Park 17 Lexington Drive Bella Vista NSW 2153 Tel: (02) 9629 0200 Fax: (02) 9629 0299 | GK | GlaxoSmithKline Australia Pty Ltd Level 4, 436-438 Johnston Street Abbotsford Vic 3067 Tel: (03) 9413 7300 Fax: (03) 8761 2410 |
| | | GM | Ascent Pharma Pty Ltd 151-153 Clarendon Street South Melbourne Vic 3205 Tel: 1800 678 302 Fax: (03) 8677 6666 |
| | | GN | Ascent Pharmaceuticals Limited 151-153 Clarendon Street South Melbourne Vic 3205 Tel: 1800 678 302 Fax: (03) 8677 6666 |

Index of Manufacturers' Codes

| <i>Code</i> | <i>Manufacturer</i> | <i>Code</i> | <i>Manufacturer</i> |
|-------------|---|-------------|--|
| GQ | Generic Health Pty Ltd Suite 1, Level 1 1175 Toorak Road Camberwell Vic 3124 Tel: (03) 9809 7900 Fax: (03) 9809 7999 | NO | Novo Nordisk Pharmaceuticals Pty Ltd Level 3, 21 Solent Circuit Baulkham Hills NSW 2153 Tel: (02) 8858 3600 Fax: (02) 8858 3799 |
| GX | GenRx A Division of Apotex Pty Ltd 66 Waterloo Road North Ryde NSW 2113 Tel: (02) 8877 8333 Fax: (02) 8877 8377 | NV | Novartis Pharmaceuticals Australia Pty Ltd 54 Waterloo Road North Ryde NSW 2113 Tel: (02) 9805 3555 Fax: (02) 9887 4551 |
| HH | Hospira Pty Ltd (David Bull Laboratories, Faulding Pharmaceuticals) Level 6, 390 St Kilda Road Melbourne Vic 3004 Tel: (03) 9868 0700 Fax: (03) 9868 0111 | PF | Pfizer Pty Limited 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9858 1347 |
| IA | iNova Pharmaceuticals (Australia) Pty Limited 9-15 Chilvers Road Thornleigh NSW 2120 Tel: (02) 9875 6333 Fax: (02) 9875 6416 | PK | Fresenius Kabi Australia Pty Limited 964 Pacific Highway Pymble NSW 2073 Tel: 1300 732 001 Fax: 1300 304 384 |
| LM | Link Medical Products Pty Ltd Unit 1, 5 Apollo Street Warriewood NSW 2102 Tel: (02) 8401 9777 Fax: (02) 8401 9786 | PL | Phebra 332 Burns Bay Road Lane Cove NSW 2066 Tel: (02) 9420 9199 Fax: (02) 9420 9177 |
| LN | Lennon Healthcare A Division of Aspen Pharmacare Australia Pty Ltd First Floor 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540 | QA | Aspen Pharma Pty Ltd 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2802 |
| MD | Macarthur Research Division of Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9981 3229 | RA | Ranbaxy Australia Pty Limited Suite 4.02, Level 4 Building D 12-24 Talavera Road North Ryde NSW 2113 Tel: (02) 9647 1172 Fax: (02) 9647 1172 |
| MF | Mundipharma Pty Ltd Level 33, 50 Bridge Street Sydney NSW 2000 Tel: (02) 9231 7200 Fax: (02) 9223 0011 | RC | Reckitt Benckiser (Australia) Pty Limited 44 Wharf Road West Ryde NSW 2114 Tel: (02) 9857 2000 Fax: (02) 9857 2004 |
| MI | Meditech Int. Pty Ltd Unit 5, 36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475 | RO | Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9971 7401 |
| MK | Merck Sharp & Dohme (Australia) Pty Ltd 54-68 Ferndell Street South Granville NSW 2142 Tel: (02) 9795 9500 Fax: (02) 9795 9595 | SW | Sanofi-Aventis Australia Pty Ltd Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000 |
| | | SZ | Sandoz Pty Ltd Level 4, Suite 7-19 100 Harris Street Pymont NSW 2009 Tel: (02) 9566 1500 Fax: (02) 9566 1458 |

Index of Manufacturers' Codes

| <i>Code</i> | <i>Manufacturer</i> | <i>Code</i> | <i>Manufacturer</i> |
|-------------|---|-------------|---------------------|
| TS | Specialised Therapeutics Australia Pty Ltd Level 1, 711 High Street Kew East Vic 3102 Tel: 1300 798 820 Fax: 1800 798 829 | | |
| TW | Terry White Chemists Level 7, 5 Queens Road Melbourne Vic 3004 Tel: (03) 9918 2500 Fax: (03) 9918 2006 | | |
| TX | Apotex Pty Ltd 66 Waterloo Road North Ryde NSW 2113 Tel: (02) 8877 8333 Fax: (02) 8877 8377 | | |
| VT | Valeant Pharmaceuticals Australasia Pty Ltd Level 7, Suite 7.02 3 Rider Boulevard Rhodes NSW 2138 Tel: 1800 630 056 Fax: (02) 9743 4053 | | |
| WQ | Willow Pharmaceuticals Pty Limited Level 31, ABN Amro Tower 88 Phillip Street Sydney NSW 2000 Tel: (02) 9518 1735 Fax: (02) 9518 1835 | | |
| YM | Symbion Pharmacy Services Pty Ltd Level 7, 5 Queens Road Melbourne Vic 3004 Tel: (03) 9918 2000 Fax: (03) 9918 2006 | | |
| YN | Mayne Pharma International Pty Ltd 1538 Main North Road Salisbury SA 5106 Tel: (08) 8209 2666 Fax: (08) 8281 6998 | | |
| YT | Mayne Products Pty Ltd 1538 Main North Road Salisbury SA 5106 Tel: (08) 8209 2666 Fax: (08) 8281 6998 | | |
| ZP | Spirit Pharmaceuticals Pty Ltd 117 Harrington Street The Rocks Sydney NSW 2000 Tel: (02) 9251 1088 Fax: (02) 9251 1099 | | |

THERAPEUTIC INDEX

| | |
|---|----|
| Alimentary tract and metabolism | 20 |
| Stomatological preparations | 20 |
| Stomatological preparations | 20 |
| Drugs for functional gastrointestinal disorders | 20 |
| Belladonna and derivatives, plain | 20 |
| Propulsives | 20 |
| Antiemetics and antinauseants | 20 |
| Antiemetics and antinauseants | 20 |
| Antidiarrheals, intestinal antiinflammatory/ antiinfective agents | 21 |
| Intestinal antiinfectives | 21 |
| Blood and blood forming organs | 22 |
| Blood substitutes and perfusion solutions | 22 |
| I.V. solutions | 22 |
| Cardiovascular system | 23 |
| Cardiac therapy | 23 |
| Antiarrhythmics, class I and III | 23 |
| Cardiac stimulants excl. cardiac glycosides | 23 |
| Vasodilators used in cardiac diseases | 23 |
| Dermatologicals | 24 |
| Corticosteroids, dermatological preparations | 24 |
| Corticosteroids, plain | 24 |
| Systemic hormonal preparations, excl. sex hormones and insulins | 25 |
| Corticosteroids for systemic use | 25 |
| Corticosteroids for systemic use, plain | 25 |
| Pancreatic hormones | 25 |
| Glycogenolytic hormones | 25 |
| Antiinfectives for systemic use | 26 |
| Antibacterials for systemic use | 26 |
| Tetracyclines | 26 |
| Beta-lactam antibacterials, penicillins | 26 |
| Other beta-lactam antibacterials | 30 |
| Sulfonamides and trimethoprim | 32 |
| Macrolides, lincosamides and streptogramins | 32 |
| Other antibacterials | 33 |
| Musculo-skeletal system | 35 |
| Antiinflammatory and antirheumatic products | 35 |
| Antiinflammatory and antirheumatic products, non-steroids | 35 |
| Nervous system | 38 |
| Analgesics | 38 |
| Opioids | 38 |
| Other analgesics and antipyretics | 40 |
| Antiepileptics | 41 |
| Antiepileptics | 41 |
| Anti-Parkinson drugs | 41 |
| Anticholinergic agents | 41 |

| | |
|---|----|
| Psycholeptics | 41 |
| Anxiolytics..... | 41 |
| Hypnotics and sedatives | 42 |
| Respiratory system | 43 |
| Drugs for obstructive airway diseases | 43 |
| Adrenergics for systemic use | 43 |
| Sensory organs | 44 |
| Ophthalmologicals..... | 44 |
| Antiinfectives | 44 |
| Various..... | 45 |
| All other therapeutic products | 45 |
| All other therapeutic products | 45 |
| All other non-therapeutic products | 45 |
| All other non-therapeutic products | 45 |

Section 2

Schedule of Benefits

SYMBOLS USED IN THE SCHEDULE

An asterisk (*) against the dispensed price of a benefit indicates that the manufacturer's pack does not coincide with the maximum quantity.

A double dagger (‡) in the maximum quantity column indicates an item for which the maximum quantity has been specially determined to correspond to the manufacturer's pack and the manufacturer's standard pack should be prescribed and supplied. For any item where a maximum quantity greater than 1 is marked with a double dagger (‡), that maximum quantity should be prescribed and supplied.

A gauge sign (#) against the dispensed price of a benefit indicates that the product is not preconstituted and that an extemporaneously-prepared dispensing fee is included in the dispensed price and, where appropriate, an amount for purified water.

Where a STATE is indicated after a manufacturer's code, that brand may be available only in the State indicated. NSW-(N); Vic-(V); Qld-(Q); SA-(S); WA-(W); Tas-(T).

RESTRICTED BENEFITS

All restricted items have separate headings for authority and non-authority items. In each case these items may be prescribed as pharmaceutical benefits only for use for one of the specified indications. Where more than one indication is specified for an Authority required or Restricted pharmaceutical benefit, each indication is separated from the preceding indication by a semi-colon and commences on the next line. In the case of Authority required (STREAMLINED) items, each indication will also include a four digit streamlined authority code. The drug may be prescribed as a pharmaceutical benefit for a patient who qualifies under any of the specified indications.

A straight line is drawn between entries for different forms and strengths of an item to indicate clearly the different restrictions which apply to these various forms and strengths.

The maximum quantity and/or number of repeats in respect of an item shown in the Schedule may be varied by the Chief Executive Officer of Medicare Australia when approving an Authority Prescription or an Authority to Prescribe. The quantity and number of repeats shown on the authority shall be supplied. (See Explanatory Notes). Payment will be made on the basis of the price shown for that item in the Schedule.

CODES FOR INJECTABLE ITEMS WITH ALLOWABLE SOLVENTS

The entry in this schedule of those pharmaceutical benefit injectable items which require a solvent includes the codes of the items with the relevant solvents. For each such item the code is for the injectable with 10mL sodium chloride injection 9 mg per mL (0.9%).

BRAND EQUIVALENCE

'a' located immediately before brand names of a particular strength of an item indicates that the sponsors of these brands have submitted evidence that they have been demonstrated to be bioequivalent or therapeutically equivalent, or that justification for not needing bioequivalence or therapeutic equivalence data has been provided to and accepted by the Therapeutic Goods Administration. It would thus be expected that these brands may be interchanged without differences in clinical effect.

For other brands of an item, i.e., those not indicated as above, it is unknown whether or not they are equivalent. There may be several reasons for this, such as bioequivalence data not being considered necessary when the products were approved for marketing, or that advice or data have not been forthcoming from sponsors. This does not necessarily suggest a lack of safety or efficacy, but in these circumstances caution should be taken if brands are interchanged.

'b' attached to brand names indicates that these brands are also equivalent, but that it is not known if there is equivalence between brands marked 'a' and brands marked 'b'.

BRAND PREMIUM POLICY

The Brand Premium Policy was introduced on 1 December 1990 to increase price competition by allowing pharmaceutical manufacturers to set their own price on multi-branded items listed on the Pharmaceutical Benefits Scheme and to encourage the development of the generic pharmaceutical industry in Australia. The policy does this by increasing prescribers' and patients' consciousness about the price of drugs. In effect, it makes both groups question whether it is

necessary for the patient to pay more for the drugs when a cheaper brand is available. The policy also allows companies to establish prices taking into account competition and consumer acceptance.

The policy operates where there is more than one brand of a particular drug available through the Pharmaceutical Benefits Scheme and where the brands are therapeutically interchangeable. Due to this, the policy mainly applies to out of patent drugs.

Basically the policy operates by:

- the Australian Government subsidising a drug to the level of the lowest priced brand (except in those instances where the lowest priced brand has, as part of its price, a therapeutic group premium);
- suppliers of other brands of that drug being able to set a price above the price charged by the supplier(s) of the lowest priced brand(s); and
- the patient paying the brand premium which is the price difference between the lowest price brand and the brand prescribed.

If a prescription is written generically or for the lowest priced brand, and the lowest priced brand is supplied, there is no brand premium payable.

'B' located immediately before an amount in the premium column indicates a brand premium which applies to that particular brand of the item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

If a brand of a drug which is subject to a special patient contribution also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'S' and 'B' respectively.

THERAPEUTIC GROUP PREMIUM POLICY

The Therapeutic Group Premium Policy was introduced on 1 February 1998 as an extension of the Brand Premium Policy to encourage greater competition between manufacturers of drugs and to make doctors and patients more aware of the costs of medicines.

The Therapeutic Group Premium policy applies within narrowly defined therapeutic sub-groups where the drugs concerned are of similar safety, efficacy and health outcomes.

Basically the policy operates by:

- the Australian Government subsidising drugs within a defined therapeutic sub-group to the level of the lowest priced drug in the sub-group;
- suppliers of other drugs within that sub-group being able to set prices above the price charged by the supplier(s) of the lowest priced drug; and
- the patient paying the therapeutic group premium which is the price difference between the lowest price drug and the drug prescribed.

'T' located immediately before an amount in the premium column indicates a therapeutic group premium which applies to that particular item.

If a brand of a drug which is subject to a therapeutic group premium also has a brand premium, there will be two amounts shown on separate lines in the premium column, prefixed by 'T' and 'B' respectively.

The success of the Government in controlling prices of products supplied through the Pharmaceutical Benefits Scheme has often been criticised by the pharmaceutical industry. Under both the Brand Premium Policy and the Therapeutic Group Premium Policy, suppliers of multi-branded items and therapeutically similar drugs are able to set their own prices at a level that they think the market will bear. At the same time, the prescriber and the patient can decide whether it is necessary to pay more for a particular brand or drug when a cheaper one is available and is therapeutically interchangeable.

The brand premium or therapeutic group premium does not count toward the patient's safety net.

It should be noted that the brand premium or therapeutic group premium is not a Government charge or revenue. The premium arises from the manufacturer's price and the majority goes to the manufacturer with wholesalers and pharmacists receiving a small percentage.

SPECIAL PHARMACEUTICAL BENEFITS

The special patient contribution is payable by all patients in addition to the relevant patient contribution for concessional and general patients. Other than for bleomycin sulfate, exemptions on medical grounds are available. For eligible veterans under RPBS provisions, see RPBS EXPLANATORY NOTES, paragraph 32.

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Reimbursement Price for Max. Qty \$ | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--|-----------------------------|
|------|---|-------------|----------------|---------|--|--|--|-----------------------------|

Antiinfectives for systemic use

Antibacterials for systemic use

Beta-lactam antibacterials, penicillins
Penicillins with extended spectrum

| | | | | | | | | | |
|-------|--|----|----|--------|--------|--------|-------|--------|----|
| 3310F | AMOXYCILLIN Powder for paediatric oral drops 100 mg per mL, 20 mL | #1 | .. | \$0.61 | #13.23 | #13.84 | 14.67 | Amoxil | GK |
|-------|--|----|----|--------|--------|--------|-------|--------|----|

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|-----------------------|---|-----------------------------|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |

Alimentary tract and metabolism

Stomatological preparations

Stomatological preparations

Antiinfectives and antiseptics for local oral treatment

| | | | | | | | | |
|---------------------|---|----|----|----|-------|-------|-----------------------|----------|
| AMPHOTERICIN | | | | | | | | |
| 3306B | Lozeng 10 mg | 20 | .. | .. | 12.03 | 13.12 | Fungilin | QA |
| NYSTATIN | | | | | | | | |
| 3343Y | Oral suspension 100,000 units per mL, 24 mL | ¥1 | .. | .. | 10.85 | 11.94 | Mycostatin Nilstat | FM QA |

Other agents for local oral treatment

| | | | | | | | | |
|----------------------------------|---|----|----|----|-------|-------|---------|----|
| BENZYDAMINE HYDROCHLORIDE | | | | | | | | |
| Restricted benefit | | | | | | | | |
| Radiation induced mucositis. | | | | | | | | |
| 5032W | Mouth and throat rinse 22.5 mg per 15 mL, 500 mL | ¥1 | .. | .. | 22.26 | 23.35 | Difflam | IA |

Drugs for functional gastrointestinal disorders

Belladonna and derivatives, plain

Belladonna alkaloids, tertiary amines

| | | | | | | | | |
|-----------------|---|----|----|----|-------|-------|-----------------------------|----|
| ATROPINE | | | | | | | | |
| 5022H | Injection containing atropine sulfate 600 micrograms in 1 mL | 10 | .. | .. | 20.54 | 21.63 | Pfizer Australia Pty Ltd | PF |

Propulsives

Propulsives

| | | | | | | | | |
|-------------------------------------|-------------------------|----|----|----|-------------------|-------|---------|----|
| METOCLOPRAMIDE HYDROCHLORIDE | | | | | | | | |
| 5151D | Tablet 10 mg | 25 | .. | .. | 8.20 | 9.29 | Pramin | AF |
| | | | | | ^B 3.02 | 11.22 | Maxolon | VT |
| 5153F | Injection 10 mg in 2 mL | 10 | .. | .. | 12.99 | 14.08 | Maxolon | VT |

Antiemetics and antinauseants

Antiemetics and antinauseants

Other antiemetics

| | | | | | | | | |
|---|---|----|----|----|-------------------|-------|--|----------------------------|
| PROCHLORPERAZINE | | | | | | | | |
| Caution | | | | | | | | |
| Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only. | | | | | | | | |
| 5205Y | Tablet containing prochlorperazine maleate 5 mg | 25 | .. | .. | 9.46 | 10.55 | ^a APO- Prochlorperazine ^a ProCalm ^a Prochlorperazine- GA ^a Stemetil | TX QA GM AV SW |
| | | | | | ^B 3.45 | 12.91 | ^a Stemetil | SW |
| 5206B | Injection containing prochlorperazine mesylate 12.5 mg in 1 mL | 10 | .. | .. | 16.82 | 17.91 | Stemetil | SW |
| 5208D | Suppositories containing prochlorperazine | ¥1 | .. | .. | 19.93 | 21.02 | Stemetil | SW |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer | |
|-------|---|-------------|-------------|---------|--|--|-----------------------------|----|
| | equivalent to 25 mg prochlorperazine maleate, 5 | | | | | | | |
| | PROMETHAZINE HYDROCHLORIDE | | | | | | | |
| 3374N | Injection 50 mg in 2 mL | 10 | .. | .. | *22.32 | 23.41 | Hospira Pty Limited | HH |

| |
|---|
| Antidiarrheals, intestinal antiinflammatory/ antiinfective agents |
|---|

Intestinal antiinfectives

Antibiotics

| | | | | | | | | |
|-------|-----------------------|----|----|----|-------|-------|---------|----|
| | NYSTATIN | | | | | | | |
| 3342X | Tablet 500,000 units | 50 | .. | .. | 17.98 | 19.07 | Nilstat | QA |
| 3345C | Capsule 500,000 units | 50 | .. | .. | 17.98 | 19.07 | Nilstat | QA |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|-----------------------|---|-----------------------------|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |

Blood and blood forming organs

Blood substitutes and perfusion solutions

I.V. solutions

Solutions for parenteral nutrition

GLUCOSE

| | | | | | | | | |
|-------|--|---|----|----|--------|-------|---|----|
| 5005K | I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL | 5 | .. | .. | *17.87 | 18.96 | ^a B. Braun Australia Pty Ltd | BR |
| | | | | | | | ^a Fresenius Kabi Australia Pty Limited | PK |
| 5106R | I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L | 5 | .. | .. | *22.82 | 23.91 | ^a B. Braun Australia Pty Ltd | BR |
| | | | | | | | ^a Baxter Healthcare Pty Ltd | BX |
| | | | | | | | ^a Fresenius Kabi Australia Pty Limited | PK |

Solutions affecting the electrolyte balance

SODIUM CHLORIDE

| | | | | | | | | |
|-------|---|---|----|----|--------|-------|---|----|
| 5021G | I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL | 5 | .. | .. | *13.02 | 14.11 | ^a B. Braun Australia Pty Ltd | BR |
| | | | | | | | ^a Fresenius Kabi Australia Pty Limited | PK |
| 5212H | I.V. infusion 154 mmol per L (0.9%), 1 L | 5 | .. | .. | *15.92 | 17.01 | ^a B. Braun Australia Pty Ltd | BR |
| | | | | | | | ^a Baxter Healthcare Pty Ltd | BX |
| | | | | | | | ^a Fresenius Kabi Australia Pty Limited | PK |
| 5213J | I.V. infusion 513 mmol per L (3%), 1 L | 2 | .. | .. | *12.12 | 13.21 | Baxter Healthcare Pty Ltd | BX |

SODIUM CHLORIDE with GLUCOSE

| | | | | | | | | |
|-------|--|---|----|----|--------|-------|---------------------------|----|
| 5214K | I.V. infusion 31 mmol-222 mmol (anhydrous) per L (0.18%-4%), 1 L | 5 | .. | .. | *23.52 | 24.61 | Baxter Healthcare Pty Ltd | BX |
| 5215L | I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL (0.225%-3.75%), 500 mL | 5 | .. | .. | *28.77 | 29.86 | Baxter Healthcare Pty Ltd | BX |
| 5216M | I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL (0.45%-2.5%), 500 mL | 5 | .. | .. | *28.77 | 29.86 | Baxter Healthcare Pty Ltd | BX |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|--|--|-----------------------------|
|------|---|-------------|-------------|---------|--|--|-----------------------------|

Cardiovascular system

Cardiac therapy

Antiarrhythmics, class I and III

Antiarrhythmics, class IB

LIGNOCAINE HYDROCHLORIDE

| | | | | | | | | |
|-------|--------------------------|---|----|----|-------|-------|--------------------------|----|
| 5142P | Injection 100 mg in 5 mL | 5 | .. | .. | 37.33 | 34.20 | Pfizer Australia Pty Ltd | PF |
|-------|--------------------------|---|----|----|-------|-------|--------------------------|----|

Cardiac stimulants excl. cardiac glycosides

Adrenergic and dopaminergic agents

ADRENALINE

| | | | | | | | | |
|-------|-------------------------------------|---|----|----|-------|-------|-------------------------------|----|
| 5004J | Injection 1 mg in 1 mL (1 in 1,000) | 5 | .. | .. | 20.34 | 21.43 | Link Medical Products Pty Ltd | LM |
|-------|-------------------------------------|---|----|----|-------|-------|-------------------------------|----|

Vasodilators used in cardiac diseases

Organic nitrates

GLYCERYL TRINITRATE

| | | | | | | | | |
|-------|-----------------------------|----|----|-------------------|-------|--------------------|---------------------|----|
| 5108W | Tablets 600 micrograms, 100 | ‡1 | .. | .. | 14.83 | 15.92 ^a | Lycinate | FM |
| | | | | ^B 2.94 | 17.77 | 15.92 ^a | Anginine Stabilised | QA |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|-----------------------|---|-----------------------------|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |

Dermatologicals

Corticosteroids, dermatological preparations

Corticosteroids, plain

Corticosteroids, weak (group I)

HYDROCORTISONE ACETATE

Restricted benefit

Treatment of corticosteroid-responsive dermatoses.

| | | | | | | | | | |
|-------|---|----|----|-------------------|-------|------|--------------|---------------------------|----|
| 5111B | Cream 10 mg per g (1%), 30 g | ‡1 | .. | .. | 8.89 | 9.98 | ^a | Cortic-DS 1% Sigmacort | FM |
| | | | | ^B 2.69 | 11.58 | 9.98 | ^a | | QA |
| 5112C | Topical ointment 10 mg per g (1%), 30 g | ‡1 | .. | .. | 8.89 | 9.98 | ^a | Cortic-DS 1% Sigmacort | FM |
| | | | | ^B 2.69 | 11.58 | 9.98 | ^a | | QA |
| 5113D | Cream 10 mg per g (1%), 50 g | ‡1 | .. | .. | 8.56 | 9.65 | ^a | Cortic-DS 1% Sigmacort | FM |
| | | | | ^B 2.70 | 11.26 | 9.65 | ^a | | QA |
| 5114E | Topical ointment 10 mg per g (1%), 50 g | ‡1 | .. | .. | 8.56 | 9.65 | ^a | Cortic-DS 1% Sigmacort | FM |
| | | | | ^B 2.70 | 11.26 | 9.65 | ^a | | QA |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|-----------------------|---|-----------------------------|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |

Systemic hormonal preparations, excl. sex hormones and insulins

Corticosteroids for systemic use

Corticosteroids for systemic use, plain

Glucocorticoids

BETAMETHASONE ACETATE with BETAMETHASONE SODIUM PHOSPHATE

Restricted benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

| | | | | | | | | |
|-------|--|---|----|----|-------|-------|-------------------------|----|
| 5034Y | Injection 3 mg-3.9 mg (equivalent to 5.7 mg betamethasone) in 1 mL | 5 | .. | .. | 25.00 | 26.09 | Celestone Chronodose | MK |
|-------|--|---|----|----|-------|-------|-------------------------|----|

HYDROCORTISONE SODIUM SUCCINATE

Restricted benefit

For use in a hospital.

| | | | | | | | | |
|-------|---|---|----|----|--------|-------|-------------|----|
| 5118J | Injection equivalent to 100 mg hydrocortisone with 2 mL solvent | 6 | .. | .. | *36.72 | 34.20 | Solu-Cortef | PF |
|-------|---|---|----|----|--------|-------|-------------|----|

| | | | | | | | | |
|-------|---|---|----|----|--------|-------|-------------|----|
| 5119K | Injection equivalent to 250 mg hydrocortisone with 2 mL solvent | 6 | .. | .. | *58.74 | 34.20 | Solu-Cortef | PF |
|-------|---|---|----|----|--------|-------|-------------|----|

METHYLPREDNISOLONE ACETATE

Restricted benefit

For local intra-articular or peri-articular infiltration.

| | | | | | | | | |
|-------|-------------------------|---|----|-------------------|-------|-------|---------------|----|
| 5148Y | Injection 40 mg in 1 mL | 5 | .. | .. | 21.38 | 22.47 | Depo-Nisolone | FZ |
| | | | | ^B 0.60 | 21.98 | 22.47 | | |

TRIAMCINOLONE ACETONIDE

Restricted benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

| | | | | | | | | |
|-------|-------------------------|---|----|----|-------|-------|--------------|----|
| 5233K | Injection 10 mg in 1 mL | 5 | .. | .. | 25.00 | 26.09 | Kenacort-A10 | QA |
|-------|-------------------------|---|----|----|-------|-------|--------------|----|

Pancreatic hormones

Glycogenolytic hormones

Glycogenolytic hormones

GLUCAGON HYDROCHLORIDE

| | | | | | | | | |
|-------|---|---|----|----|-------|-------|------------------|----|
| 5105Q | Injection set containing 1 mg (1 i.u.) and 1 mL solvent in disposable syringe | 1 | .. | .. | 45.63 | 34.20 | Glucagen Hypokit | NO |
|-------|---|---|----|----|-------|-------|------------------|----|

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|-----------------------|---|-----------------------------|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |

Antiinfectives for systemic use

Antibacterials for systemic use

Tetracyclines

Tetracyclines

DOXYCYCLINE

Note

Bioequivalence has been demonstrated between doxycycline tablet 100 mg (as hydrochloride) and doxycycline tablet 100 mg (as monohydrate).

| | | | | | | | | |
|-------|-----------------------------------|---|----|----|-------------------|------|--------------------------------|----|
| 3321T | Tablet 100 mg (as hydrochloride) | 7 | .. | .. | 8.36 | 9.45 | ^a Doxsig | QA |
| | | | | | | | ^a Doxy-100 | GM |
| | | | | | | | ^a Doxylin 100 | AF |
| 5082L | Tablet 100 mg (as monohydrate) | 7 | .. | .. | 8.36 | 9.45 | ^a Chem mart | CH |
| | | | | | | | ^a Doxycycline | |
| | | | | | | | ^a Doxyhexal | SZ |
| | | | | | | | ^a GenRx Doxycycline | GX |
| | | | | | | | ^a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Doxycycline | |
| <hr/> | | | | | | | | |
| 3322W | Capsule 100 mg (as hydrochloride) | 7 | .. | .. | 8.36 | 9.45 | ^a Mayne Pharma | YT |
| | | | | | ^B 1.10 | 9.46 | ^a Doryx | YN |

Beta-lactam antibacterials, penicillins

Penicillins with extended spectrum

AMOXYCILLIN

| | | | | | | | | |
|-------|----------------|----|----|----|-------------------|-------|---------------------------------|----|
| 3300Q | Capsule 500 mg | 20 | .. | .. | 10.45 | 11.54 | ^a Alphamox 500 | AF |
| | | | | | | | ^a Amoxicillin-GA | GM |
| | | | | | | | ^a Amoxicillin | GQ |
| | | | | | | | ^a Amoxicillin | RA |
| | | | | | | | ^a Amoxicillin | RA |
| | | | | | | | ^a Amoxicillin Sandoz | SZ |
| | | | | | | | ^a APO-Amoxicillin | TX |
| | | | | | | | ^a Chem mart | CH |
| | | | | | | | ^a Amoxicillin | CH |
| | | | | | | | ^a Cilamox | QA |
| | | | | | | | ^a GenRx Amoxicillin | GX |
| 3301R | Capsule 250 mg | 20 | .. | .. | ^B 1.35 | 11.80 | ^a Amoxil | GK |
| | | | | | 8.44 | 9.53 | ^a Alphamox 250 | AF |
| | | | | | | | ^a Amoxicillin-GA | GM |
| | | | | | | | ^a Amoxicillin | RA |
| | | | | | | | ^a Amoxicillin | RA |
| | | | | | | | ^a Amoxicillin Sandoz | SZ |
| | | | | | | | ^a APO-Amoxicillin | TX |
| | | | | | | | ^a Chem mart | CH |
| | | | | | | | ^a Amoxicillin | CH |
| | | | | | | | ^a Cilamox | QA |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|---|--|-------------|-------------|-------------------|--|--|---|
| | | | | | | | ^a GenRx Amoxicillin GX |
| | | | | | | | ^a Terry White Chemists Amoxicillin TW |
| | | | | ^B 1.36 | 9.80 | 9.53 | ^a Amoxil GK |
| 3302T | Powder for syrup 125 mg per 5 mL, 100 mL | ‡1 | .. | .. | #10.81 | 12.25 | ^a Alphamox 125 AF ^a Amoxicillin Sandoz SZ ^a Bgramin GM ^a Chem mart CH ^a GenRx Amoxicillin GX ^a Ranmoxy RA ^a Terry White Chemists Amoxicillin TW |
| | | | | ^B 1.35 | #12.16 | 12.25 | ^a Amoxil GK |
| 3309E | Sachet containing oral powder 3 g | 1 | .. | .. | 8.97 | 10.06 | Amoxil GK |
| 3393N | Powder for syrup 250 mg per 5 mL, 100 mL | ‡1 | .. | .. | #11.60 | 13.04 | ^a Alphamox 250 AF ^a Amoxicillin Sandoz SZ ^a Bgramin GM ^a Chem mart CH ^a Cilamox QA ^a GenRx Amoxicillin GX ^a Ranmoxy RA ^a Terry White Chemists Amoxicillin TW |
| | | | | ^B 1.36 | #12.96 | 13.04 | ^a Amoxil Forte GK |
| 5225B | Powder for oral suspension 500 mg per 5 mL, 100 mL | ‡1 | .. | .. | #14.46 | 15.90 | Maxamox SZ |
| AMPICILLIN | | | | | | | |
| 3313J | Powder for injection 500 mg | 5 | .. | .. | 10.85 | 11.94 | ^a Austrapen LN ^a Ibimicyn TS |
| 3314K | Powder for injection 1 g | 5 | .. | .. | 13.69 | 14.78 | ^a Aspen Ampicyn AS ^a Austrapen LN ^a Ibimicyn TS |
| Beta-lactamase sensitive penicillins | | | | | | | |
| BENZATHINE BENZYL PENICILLIN | | | | | | | |
| 5027N | Injection 900 mg in 2.3 mL single use pre-filled syringe | 10 | .. | .. | 293.11 | 34.20 | Bicillin L-A AS |
| BENZYL PENICILLIN | | | | | | | |
| 3398W | Powder for injection 600 mg | 10 | .. | .. | *42.92 | 34.20 | BenPen CS |
| 3399X | Powder for injection 3 g | 10 | .. | .. | *66.92 | 34.20 | BenPen CS |
| PHENOXYMETHYL PENICILLIN | | | | | | | |
| 3360W | Tablet 250 mg | 50 | .. | .. | *11.32 | 12.41 | Abbecillin-VK Filmstab QA |
| 3361X | Tablet 500 mg | 50 | .. | .. | *13.66 | 14.75 | Abbecillin-VK Filmstab QA |
| 3363B | Capsule 250 mg | 50 | .. | .. | 11.16 | 12.25 | ^a Cilicaine VK FM ^a Cilopen VK GM LPV VT |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|----------------------------|--|-------------|-------------|-------------------------|--|--|--|
| 3364C | Capsule 500 mg | 50 | .. | .. | 13.47 | 14.56 | ^a Cilicaine VK FM ^a Cilopen VK GM LPV VT |
| 5012T | Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL | 2 | .. | .. ^B 1.90 | *21.60 *23.50 | 22.69 | ^a Cilicaine V FM ^a Abdocillin-V QA |
| 5024K | Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL | 2 | .. | .. | *#16.76 | 18.20 | Phenoxymethyl- penicillin-AFT AE |
| 5029Q | Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL | 2 | .. | .. | *#19.32 | 20.76 | Phenoxymethyl- penicillin-AFT AE |
| PROCAINE PENICILLIN | | | | | | | |
| 3371K | Injection 1.5 g | 5 | .. | .. | 92.22 | 34.20 | Cilicaine QA |

Beta-lactamase resistant penicillins

DICLOXACILLIN

Restricted benefit

Serious staphylococcal infections.

| | | | | | | | |
|-------|----------------|----|----|----|-------|-------|--|
| 5096F | Capsule 250 mg | 24 | .. | .. | 11.19 | 12.28 | ^a Dicloxsig QA ^a Distaph 250 AF |
| 5097G | Capsule 500 mg | 24 | .. | .. | 16.41 | 17.50 | ^a Diclocil BQ ^a Dicloxsig QA ^a Distaph 500 AF |

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

| | | | | | | | |
|-------|-----------------------------|---|----|----|-------|-------|--|
| 5094D | Powder for injection 500 mg | 5 | .. | .. | 15.05 | 16.14 | ^a Flubiclox TS ^a Flucil AS |
| 5095E | Powder for injection 1 g | 5 | .. | .. | 19.94 | 21.03 | ^a Flubiclox TS ^a Flucil AS ^a Hospira Pty Limited HH |

FLUCLOXACILLIN

Caution

Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.

Restricted benefit

Serious staphylococcal infections.

| | | | | | | | |
|-------|---|----|----|----|--------|-------|---|
| 5090X | Capsule 250 mg (as sodium) | 24 | .. | .. | 11.19 | 12.28 | ^a Flopen AS ^a Staphylex 250 AF |
| 5091Y | Capsule 500 mg (as sodium) | 24 | .. | .. | 16.41 | 17.50 | ^a Flopen AS ^a Staphylex 500 AF |
| 5257Q | Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL | ‡1 | .. | .. | #16.05 | 17.49 | Flucil LN |
| 5258R | Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL | ‡1 | .. | .. | #19.58 | 21.02 | Flucil LN |

Combinations of penicillins, incl. beta-lactamase inhibitors

AMOXYCILLIN with CLAVULANIC ACID

Caution

Hepatotoxicity has been reported with this drug.

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|---|---|-------------|-------------|---------|-----------------------|---|---|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |
| Other beta-lactam antibacterials | | | | | | | |
| First-generation cephalosporins | | | | | | | |
| CEFALOTIN | | | | | | | |
| 3376Q | Powder for injection 1 g | 10 | .. | .. | 26.25 | 27.34 | a Cefalotin Sandoz SZ a Hospira Pty Limited HH a Keflin Neutral AS |
| CEPHALEXIN | | | | | | | |
| 3317N | Capsule 250 mg | 20 | .. | .. | 8.72 | 9.81 | a Cefalexin Sandoz SZ a Cephalixin GQ generichealth a Cephatrust 250 MI a Chem mart CH Cephalixin a Cilex GM a GenRx Cephalixin GX a Ialex LN a Ibilex 250 AF a Pharmacor CR Cephalixin 250 a Rancef RA a Terry White TW Chemists Cephalixin |
| 3318P | Capsule 500 mg | 20 | .. | .. | 10.55 | 11.64 | ^B 3.14 11.86 9.81 a Keflex AS a Cefalexin Sandoz SZ a Cephabell BF a Cephalixin GQ generichealth a Cephatrust 500 MI a Chem mart CH Cephalixin a Cilex GM a GenRx Cephalixin GX a Ialex LN a Ibilex 500 AF a Pharmacor CR Cephalixin 500 a Rancef RA a Terry White TW Chemists Cephalixin |
| 3319Q | Granules for syrup 125 mg per 5 mL, 100 mL | ‡1 | .. | .. | #11.74 | 13.18 | ^B 4.20 14.75 11.64 a Keflex AS a APO-Cephalixin TX a Cefalexin Sandoz SZ a Chem mart CH Cephalixin a Cilex GM a GenRx Cephalixin GX a Ialex LN a Ibilex 125 AF a Terry White TW Chemists Cephalixin |
| 3320R | Granules for syrup 250 mg per 5 mL, 100 mL | ‡1 | .. | .. | #13.07 | 14.51 | ^B 3.38 #15.12 13.18 a Keflex AS a APO-Cephalixin TX |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|------|---|-------------|-------------|-------------------|--|--|---|
| | | | | | | | ^a Cefalexin Sandoz SZ |
| | | | | | | | ^a Chem mart CH Cephalexin |
| | | | | | | | ^a Cilex GM |
| | | | | | | | ^a GenRx Cephalexin GX |
| | | | | | | | ^a Ialex LN |
| | | | | | | | ^a Ibilex 250 AF |
| | | | | | | | ^a Terry White TW Chemists Cephalexin |
| | | | | ^B 4.16 | #17.23 | 14.51 | ^a Keflex AS |

Second-generation cephalosporins

CEFACTOR

Caution

Serum sickness-like reactions have been reported with this drug, especially in children.

| | | | | | | | |
|-------|---|----|----|-------------------|--------|-------|---|
| 5045M | Tablet 375 mg (sustained release) | 10 | .. | .. | 12.57 | 13.66 | ^a Cefaclor-GA GN Chem mart CH Cefaclor CD ^a Douglas Cefaclor- GM CD ^a GenRx Cefaclor CD GX ^a Karlor CD LN ^a Keflor CD AF ^a Ozcef RA ^a Terry White TW Chemists Cefaclor CD |
| | | | | ^B 4.94 | 17.51 | 13.66 | ^a Ceclor CD AS |
| 5046N | Powder for oral suspension 125 mg per 5 mL, 100 mL | ‡1 | .. | .. | #13.32 | 14.76 | ^a Aclor 125 QA ^a Cefaclor Sandoz SZ ^a Chem mart CH Cefaclor ^a GenRx Cefaclor GX ^a Keflor AF ^a Ozcef RA ^a Terry White TW Chemists Cefaclor |
| | | | | ^B 3.97 | #17.29 | 14.76 | ^a Ceclor AS |
| 5047P | Powder for oral suspension 250 mg per 5 mL, 75 mL | ‡1 | .. | .. | #13.63 | 15.07 | ^a Aclor 250 QA ^a Cefaclor Sandoz SZ ^a Chem mart CH Cefaclor ^a GenRx Cefaclor GX ^a Keflor AF ^a Ozcef RA ^a Terry White TW Chemists Cefaclor |
| | | | | ^B 4.16 | #17.79 | 15.07 | ^a Ceclor AS |
| | CEFUROXIME AXETIL | | | | | | |
| 5052X | Tablet 250 mg (base) | 14 | .. | .. | 18.62 | 19.71 | Zinnat GK |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|---|---|-------------|-------------|-------------------|--|--|--|
| Third-generation cephalosporins | | | | | | | |
| CEFOTAXIME | | | | | | | |
| Restricted benefit | | | | | | | |
| Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent. | | | | | | | |
| 5048Q | Powder for injection 1 g | 10 | .. | .. | *26.32 26.44 | 27.41 ^a 27.53 ^a | Cefotaxime Sandoz SZ Hospira Pty Limited HH |
| 5049R | Powder for injection 2 g | 10 | .. | .. | *42.92 43.02 | 34.20 ^a 34.20 ^a | Cefotaxime Sandoz SZ Hospira Pty Limited HH |
| Sulfonamides and trimethoprim | | | | | | | |
| Combinations of sulfonamides and trimethoprim, incl. derivatives | | | | | | | |
| TRIMETHOPRIM with SULFAMETHOXAZOLE | | | | | | | |
| Caution | | | | | | | |
| There is an increased risk of severe adverse reactions with this combination in the elderly. | | | | | | | |
| 3390K | Tablet 160 mg-800 mg | 10 | .. | .. | 9.24 | 10.33 ^a | Bactrim DS RO Resprim Forte AF |
| | | | | ^B 1.46 | 10.70 | 10.33 ^a | Septrin Forte QA |
| 3391L | Oral suspension 40 mg-200 mg per 5 mL, 100 mL | ‡1 | .. | .. | 8.93 | 10.02 | Bactrim RO |
| | | | | ^B 1.79 | 10.72 | 10.02 | Septrin QA |
| Macrolides, lincosamides and streptogramins | | | | | | | |
| Macrolides | | | | | | | |
| ERYTHROMYCIN | | | | | | | |
| 3325B | Capsule 250 mg | 25 | .. | .. | 9.28 | 10.37 ^a | Mayne Pharma YT Erythromycin |
| | | | | ^B 1.28 | 10.56 | 10.37 ^a | Eryc YN |
| ERYTHROMYCIN ETHYL SUCCINATE | | | | | | | |
| 3334L | Powder for oral liquid 200 mg (base) per 5 mL, 100 mL | ‡1 | .. | .. | #12.20 | 13.64 ^a | E-Mycin 200 AF |
| | | | | ^B 2.72 | #14.92 | 13.64 ^a | E.E.S. 200 LM |
| 3336N | Tablet 400 mg (base) | 25 | .. | .. | 10.69 | 11.78 ^a | E-Mycin AF |
| | | | | ^B 2.66 | 13.35 | 11.78 ^a | E.E.S. 400 Filmstab LM |
| 3337P | Powder for oral liquid 400 mg (base) per 5 mL, 100 mL | ‡1 | .. | .. | #13.23 | 14.67 ^a | E-Mycin 400 AF |
| | | | | ^B 2.74 | #15.97 | 14.67 ^a | E.E.S. Granules LM |
| ERYTHROMYCIN LACTOBIONATE | | | | | | | |
| 5088T | Powder for I.V. infusion 1 g (base) | 5 | .. | .. | *88.92 | 34.20 | Erythrocin-I.V. LM |
| ROXITHROMYCIN | | | | | | | |
| 5259T | Tablet for oral suspension 50 mg | 10 | .. | .. | 12.89 | 13.98 | Rulide D SW |
| 5260W | Tablet 150 mg | 10 | .. | .. | 11.49 | 12.58 ^a | APO-Roxithromycin TX Biaxsig AV Chem mart CH Roxithromycin Roxar 150 QA Roxide SZ Roximycin AF Roxithromycin-GA GM Terry White TW Chemists Roxithromycin |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|---|--|-------------|-------------|-------------------|--|--|---|
| | | | | ^B 2.60 | 14.09 | 12.58 | ^a Rulide SW |
| 5261X | Tablet 300 mg | 5 | .. | .. | 11.49 | 12.58 | ^a APO-Roxithromycin TX ^a Biaxsig AV ^a Chem mart CH ^a Roxithromycin ^a Roxar 300 QA ^a Roxide SZ ^a Roximycin AF ^a Roxithromycin-GA GM ^a Terry White TW Chemists Roxithromycin |
| | | | | ^B 2.60 | 14.09 | 12.58 | ^a Rulide SW |
| Lincosamides | | | | | | | |
| CLINDAMYCIN | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | |
| Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin. | | | | | | | |
| 5057E | Capsule 150 mg | 24 | .. | .. | 19.75 | 20.84 | ^a Cleocin FZ |
| | | | | ^B 1.37 | 21.12 | 20.84 | ^a Dalacin C PF |
| LINCOMYCIN | | | | | | | |
| 5144R | Injection 600 mg in 2 mL | 5 | .. | .. | 33.74 | 34.20 | Lincocin PF |
| Other antibacterials | | | | | | | |
| <i>Glycopeptide antibacterials</i> | | | | | | | |
| VANCOMYCIN | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | |
| Prophylaxis of endocarditis in patients hypersensitive to penicillin. | | | | | | | |
| 3323X | Powder for injection 500 mg (as hydrochloride) (500,000 i.u. vancomycin activity) | 2 | .. | .. | *16.52 | 17.61 | ^a Hospira Pty Limited HH ^a Vancocin CP AS ^a Vancomycin AF Alphapharm ^a Vancomycin SZ Sandoz ^a Vycin IV WQ |
| 5083M | Powder for injection 1 g (as hydrochloride) (1,000,000 i.u. vancomycin activity) | 1 | .. | .. | 16.52 | 17.61 | ^a Hospira Pty Limited HH ^a Vancomycin AF Alphapharm ^a Vancomycin SZ Sandoz ^a Vycin IV WQ |
| <i>Imidazole derivatives</i> | | | | | | | |
| METRONIDAZOLE | | | | | | | |
| 3339R | Tablet 200 mg | 21 | .. | .. | 7.88 | 8.97 | ^a Metrogl 200 AF ^a Metronide 200 AV |
| | | | | ^B 2.30 | 10.18 | 8.97 | ^a Flagyl SW |
| 5157K | Suppositories 500 mg, 10 | ‡1 | .. | .. | 23.16 | 24.25 | Flagyl SW |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|--|--|-------------|-------------|-------------------|--|--|--------------------------------------|
| METRONIDAZOLE | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | |
| Treatment of anaerobic infections. | | | | | | | |
| 5155H | Tablet 400 mg | 21 | .. | .. | 9.85 | 10.94 | ^a Metrogyl 400 AF |
| | | | | | | | ^a Metronide 400 AV |
| | | | | ^B 2.30 | 12.15 | 10.94 | ^a Flagyl SW |
| <hr/> | | | | | | | |
| METRONIDAZOLE | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | |
| Treatment, in a hospital, of acute anaerobic sepsis. | | | | | | | |
| 5154G | I.V. infusion 500 mg in 100 mL | 5 | .. | .. | *30.67 | 31.76 | ^a Baxter Healthcare BX |
| | | | | .. | *31.70 | 32.79 | ^a DBL Metronidazole HH |
| | | | | | | | ^a Intravenous Infusion SZ |
| | | | | | | | ^a Metronidazole Sandoz |
| | | | | | | | |
| METRONIDAZOLE BENZOATE | | | | | | | |
| 3341W | Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL | ‡1 | .. | .. | 18.82 | 19.91 | Flagyl S SW |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|--|--|-----------------------------|
|------|---|-------------|-------------|---------|--|--|-----------------------------|

Musculo-skeletal system

Antiinflammatory and antirheumatic products

Antiinflammatory and antirheumatic products, non-steroids

Acetic acid derivatives and related substances

| | | | | | | | | |
|-------|--|-----|----|----|---------------------------------------|-------|--|--|
| 5079H | DICLOFENAC SODIUM Suppository 100 mg | 40 | .. | .. | *24.92 | 26.01 | Voltaren 100 | NV |
| <hr/> | | | | | | | | |
| 5076E | DICLOFENAC SODIUM <u>Restricted benefit</u> Chronic arthropathies (including osteoarthritis) with an inflammatory component; Bone pain due to malignant disease. | 100 | .. | .. | *12.74 | 13.83 | ^a APO-Diclofenac ^a Chem mart Diclofenac ^a Clonac 25 ^a Diclofenac-GA ^a Diclofenac Sandoz ^a Fenac 25 ^a Terry White Chemists Diclofenac | TX CH QA GM SZ AF TW |
| 5077F | Tablet 25 mg (enteric coated) | 100 | .. | .. | ^B 2.32 *15.06 | 13.83 | ^a Voltaren 25 | NV |
| 5077F | Tablet 50 mg (enteric coated) | 50 | .. | .. | 10.82 | 11.91 | ^a APO-Diclofenac ^a Chem mart Diclofenac ^a Clonac 50 ^a Diclofenac-GA ^a Diclofenac Sandoz ^a Fenac ^a Terry White Chemists Diclofenac | TX CH QA GM SZ AF TW |
| 5128X | INDOMETHACIN Suppository 100 mg | 40 | .. | .. | *22.50 | 23.59 | Indocid | AS |
| <hr/> | | | | | | | | |
| 5126T | INDOMETHACIN <u>Restricted benefit</u> Chronic arthropathies (including osteoarthritis) with an inflammatory component; Bone pain due to malignant disease. | 100 | .. | .. | *11.80 ^B 2.04 *13.84 | 12.89 | ^a Arthrexin ^a Indocid | AF AS |

Oxicams

PIROXICAM

Restricted benefit

Chronic arthropathies (including osteoarthritis) with an inflammatory component.

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer | |
|-------|---|-------------|-------------|-------------------|-----------------------|---|---|----|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | | |
| 5201R | Dispersible tablet 10 mg | 50 | .. | .. | 12.20 | 13.29 | Mobilis D-10 | AF |
| 5202T | Dispersible tablet 20 mg | 25 | .. | .. | 11.92 | 13.01 | ^a Mobilis D-20 | AF |
| | | | | ^B 2.49 | 14.41 | 13.01 | ^a Feldene-D | PF |
| 5203W | Capsule 10 mg | 50 | .. | .. | 12.20 | 13.29 | ^a Chem mart | CH |
| | | | | | | | ^a Piroxicam | |
| | | | | | | | ^a GenRx Piroxicam | GX |
| | | | | | | | ^a Mobilis 10 | AF |
| | | | | | | | ^a Terry White Chemists Piroxicam | TW |
| | | | | ^B 2.52 | 14.72 | 13.29 | ^a Feldene | PF |
| 5204X | Capsule 20 mg | 25 | .. | .. | 11.92 | 13.01 | ^a Chem mart | CH |
| | | | | | | | ^a Piroxicam | |
| | | | | | | | ^a GenRx Piroxicam | GX |
| | | | | | | | ^a Mobilis 20 | AF |
| | | | | | | | ^a Terry White Chemists Piroxicam | TW |
| | | | | ^B 2.49 | 14.41 | 13.01 | ^a Feldene | PF |

Propionic acid derivatives

| | | | | | | | | |
|------------------|---------------|----|----|----|------|-------|--------|----|
| IBUPROFEN | | | | | | | | |
| 5124Q | Tablet 400 mg | 30 | .. | .. | 9.19 | 10.28 | Brufen | AB |

IBUPROFEN

Restricted benefit

Chronic arthropathies (including osteoarthritis) with an inflammatory component;

Bone pain due to malignant disease.

| | | | | | | | | |
|-------|---------------|----|----|----|--------|-------|--------|----|
| 5123P | Tablet 400 mg | 90 | .. | .. | *14.73 | 15.82 | Brufen | AB |
|-------|---------------|----|----|----|--------|-------|--------|----|

KETOPROFEN

| | | | | | | | | |
|-------|--------------------|----|----|----|--------|-------|--------|----|
| 5139L | Suppository 100 mg | 40 | .. | .. | *25.30 | 26.39 | Orudis | SW |
|-------|--------------------|----|----|----|--------|-------|--------|----|

KETOPROFEN

Restricted benefit

Chronic arthropathies (including osteoarthritis) with an inflammatory component.

| | | | | | | | | |
|-------|------------------------------------|----|----|-------------------|-------|-------|----------------------------|----|
| 5136H | Capsule 200 mg (sustained release) | 28 | .. | .. | 19.10 | 20.19 | ^a Oruvail SR | AV |
| | | | | ^B 2.21 | 21.31 | 20.19 | ^a Orudis SR 200 | SW |

NAPROXEN

Restricted benefit

Chronic arthropathies (including osteoarthritis) with an inflammatory component;

Bone pain due to malignant disease.

| | | | | | | | | |
|-------|-----------------------------------|-----|----|-------------------|--------|-------|------------------------------|----|
| 5176K | Tablet 250 mg | 100 | .. | .. | *13.34 | 14.43 | ^a Inza 250 | AF |
| | | | | ^B 2.24 | *15.58 | 14.43 | ^a Naprosyn | RO |
| 5177L | Tablet 500 mg | 50 | .. | .. | 12.58 | 13.67 | ^a Inza 500 | AF |
| | | | | ^B 1.30 | 13.88 | 13.67 | ^a Naprosyn | RO |
| 5178M | Tablet 750 mg (sustained release) | 28 | .. | .. | 12.08 | 13.17 | ^a Proxen SR 750 | MD |
| | | | | ^B 1.22 | 13.30 | 13.17 | ^a Naprosyn SR750 | RO |
| 5179N | Tablet 1 g (sustained release) | 28 | .. | .. | 13.96 | 15.05 | ^a Proxen SR 1000 | MD |
| | | | | ^B 1.29 | 15.25 | 15.05 | ^a Naprosyn SR1000 | RO |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|--|---|-------------|-------------|-------------------|-----------------------|---|-----------------------------|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |
| NAPROXEN SODIUM | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | |
| Chronic arthropathies (including osteoarthritis) with an inflammatory component; | | | | | | | |
| Bone pain due to malignant disease. | | | | | | | |
| <u>Note</u> | | | | | | | |
| Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid. | | | | | | | |
| 5186Y | Tablet 550 mg | 50 | .. | .. | 12.77 | 13.86 ^a | Crysanal MD |
| | | | | ^B 2.17 | 14.94 | 13.86 ^a | Anaprox 550 RO |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|-----------------------|---|-----------------------------|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | |

Nervous system

Analgesics

Opioids

Natural opium alkaloids

CODEINE PHOSPHATE

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

| | | | | | | | | | |
|---|---------------------|----|----|-------------------|-------|-------|---|----|--|
| 5063L | Tablet 30 mg | 20 | .. | .. | 16.87 | 17.96 | Fawns and McAllan Proprietary Limited | FM | |
| CODEINE PHOSPHATE with PARACETAMOL | | | | | | | | | |
| 3316M | Tablet 30 mg-500 mg | 20 | .. | .. | 8.00 | 9.09 | ^a APO- Paracetamol/Code ine 500/30 | TX | |
| | | | | | | | ^a Codalgin Forte | FM | |
| | | | | | | | ^a Codapane Forte | AL | |
| | | | | | | | ^a Comfarol Forte | SZ | |
| | | | | | | | ^a Dolaforte | CO | |
| | | | | | | | ^a Prodeine Forte | AV | |
| | | | | ^b 2.80 | 10.80 | 9.09 | ^a Panadeine Forte | SW | |

HYDROMORPHONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

| | | | | | | | | |
|-------|---------------------------------|----|----|----|-------|-------|----------|----|
| 5115F | Tablet 2 mg | 20 | .. | .. | 17.10 | 18.19 | Dilaudid | MF |
| 5116G | Tablet 4 mg | 20 | .. | .. | 19.85 | 20.94 | Dilaudid | MF |
| 5117H | Tablet 8 mg | 20 | .. | .. | 30.03 | 31.12 | Dilaudid | MF |
| 5132D | Oral liquid 1 mg per mL, 473 mL | 1 | .. | .. | 63.70 | 34.20 | Dilaudid | MF |

MORPHINE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

| | | | | | | | | |
|-------|------------------------------------|---|----|----|-------|-------|-----------|----|
| 5237P | Oral solution 2 mg per mL, 200 mL | 1 | .. | .. | 17.97 | 19.06 | Ordine 2 | MF |
| 5238Q | Oral solution 5 mg per mL, 200 mL | 1 | .. | .. | 20.55 | 21.64 | Ordine 5 | MF |
| 5239R | Oral solution 10 mg per mL, 200 mL | 1 | .. | .. | 24.61 | 25.70 | Ordine 10 | MF |

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer | |
|-------|---|-------------|-------------|---------|-----------------------|---|-----------------------------|----|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | | |
| 5168B | Injection 10 mg in 1 mL | 5 | .. | .. | 13.99 | 15.08 | Hospira Pty Limited | HH |
| 5169C | Injection 15 mg in 1 mL | 5 | .. | .. | 14.35 | 15.44 | Hospira Pty Limited | HH |
| 5170D | Injection 30 mg in 1 mL | 5 | .. | .. | 15.77 | 16.86 | Hospira Pty Limited | HH |

MORPHINE SULFATE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

| | | | | | | | | |
|-------|--------------|----|----|----|-------|-------|----------|----|
| 5163R | Tablet 30 mg | 20 | .. | .. | 14.03 | 15.12 | Anamorph | FM |
|-------|--------------|----|----|----|-------|-------|----------|----|

OXYCODONE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

| | | | | | | | | |
|-------|-------------------|----|----|----|-------|-------|-----------|----|
| 5194J | Suppository 30 mg | 12 | .. | .. | 43.66 | 34.20 | Proladone | PL |
|-------|-------------------|----|----|----|-------|-------|-----------|----|

OXYCODONE HYDROCHLORIDE

Caution

The risk of drug dependence is high.

Restricted benefit

Severe disabling pain not responding to non-narcotic analgesics.

Note

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

| | | | | | | | | |
|-------|-------------------------------------|----|----|----|-------|-------|---------------------------|----|
| 5190E | Oral solution 5 mg per 5 mL, 250 mL | 1 | .. | .. | 20.72 | 21.81 | OxyNorm Liquid 5mg/5mL | MF |
| 5191F | Capsule 5 mg | 20 | .. | .. | 12.30 | 13.39 | OxyNorm | MF |
| 5195K | Tablet 5 mg | 20 | .. | .. | 12.30 | 13.39 | Endone | QA |
| 5197M | Capsule 10 mg | 20 | .. | .. | 15.42 | 16.51 | OxyNorm | MF |

Other opioids

TRAMADOL HYDROCHLORIDE

Restricted benefit

For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed;

For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed.

| | | | | | | | | |
|------------------------------|---------------|----|----|----|------|-------|-------------------------------|----|
| 5232J | Capsule 50 mg | 20 | .. | .. | 9.02 | 10.11 | ^a APO-Tramadol | TX |
| | | | | | | | ^a Chem mart | CH |
| | | | | | | | Tramadol | |
| | | | | | | | ^a GA Tramadol 50mg | GM |
| | | | | | | | ^a GenRx Tramadol | GX |
| | | | | | | | ^a Lodam 50 | ZP |
| | | | | | | | ^a Terry White | TW |
| | | | | | | | Chemists Tramadol | |
| ^a Tramadol Sandoz | SZ | | | | | | | |
| ^a Tramedo | AF | | | | | | | |
| ^a Zydol | QA | | | | | | | |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer | |
|--|---|-------------|-------------|-------------------|-----------------------|---|---|--|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | | |
| | | | | ^b 2.41 | 11.43 | 10.11 | ^a Tramal | CS |
| <hr/> | | | | | | | | |
| TRAMADOL HYDROCHLORIDE | | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | | |
| For pain where aspirin and/or paracetamol alone are inappropriate or have failed. | | | | | | | | |
| 5150C | Oral drops 100 mg per mL, 10 mL | ‡1 | .. | .. | 13.71 | 14.80 | Tramal | CS |
| <hr/> | | | | | | | | |
| TRAMADOL HYDROCHLORIDE | | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | | |
| Short-term treatment of acute pain. | | | | | | | | |
| 5231H | Injection 100 mg in 2 mL | 5 | .. | .. | 13.91 | 15.00 | ^a Tramahexal ^a Tramal 100 | SZ CS |
| Other analgesics and antipyretics <i>Salicylic acid and derivatives</i> | | | | | | | | |
| ASPIRIN | | | | | | | | |
| 5018D | Tablet 300 mg (dispersible) | 96 | .. | .. | 8.50 | 9.59 | Solprin | RC |
| Anilides | | | | | | | | |
| PARACETAMOL | | | | | | | | |
| 3348F | Oral liquid 120 mg per 5 mL, 100 mL | ‡1 | .. | .. | 9.38 | 10.47 | Panamax | SW |
| 3349G | Oral liquid 240 mg per 5 mL, 200 mL | ‡1 | .. | .. | 10.68 | 11.77 | Panamax 240 Elixir | SW |
| 5196L | Tablet 500 mg | 100 | .. | .. | 8.32 | 9.41 | ^a APO-Paracetamol ^a Chem mart Paracetamol ^a Febridol ^a Generic Health Pty Ltd ^a Panamax ^a Paracetamol Sandoz ^a Paralgin ^a Pharmacy Choice Paracetamol ^a Terry White Chemists Paracetamol | TX CH GM GQ SW SZ FM YM TW |
| <hr/> | | | | | | | | |
| PARACETAMOL | | | | | | | | |
| <u>Restricted benefit</u> | | | | | | | | |
| Chronic arthropathies. | | | | | | | | |
| 5224Y | Tablet 500 mg | 300 | .. | .. | *12.12 | 13.21 | ^a APO-Paracetamol ^a Chem mart Paracetamol ^a Febridol ^a Generic Health Pty Ltd ^a Panamax ^a Paracetamol Sandoz ^a Paralgin ^a Pharmacy Choice | TX CH GM GQ SW SZ FM YM |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|--|--|-----------------------------------|
| | | | | | | | Paracetamol |
| | | | | | | | ^a Terry White Chemists |
| | | | | | | | Paracetamol TW |

Antiepileptics

Antiepileptics

Carboxamide derivatives

CARBAMAZEPINE

| | | | | | | | | |
|-------|---|-----|----|-------------------|--------|-------|-----------------------------------|----|
| 5037D | Tablet 400 mg (controlled release) | 200 | .. | .. | 49.02 | 34.20 | Tegretol CR 400 | NV |
| 5038E | Tablet 200 mg (controlled release) | 200 | .. | .. | 29.48 | 30.57 | Tegretol CR 200 | NV |
| 5039F | Tablet 100 mg | 200 | .. | ^B 2.96 | *21.46 | 19.59 | ^a Tegretol 100 | NV |
| | | | | .. | 18.51 | 19.60 | ^a Carbamazepine Sandoz | SZ |
| 5040G | Tablet 200 mg | 200 | .. | ^B 2.96 | *31.96 | 30.09 | ^a Tegretol 200 | NV |
| | | | | .. | 29.02 | 30.11 | ^a Carbamazepine Sandoz | SZ |
| | | | | | | | ^a Teril | AF |
| 5041H | Oral suspension 100 mg per 5 mL, 300 mL | ≠1 | .. | .. | 21.35 | 22.44 | Tegretol Liquid | NV |

Anti-Parkinson drugs

Anticholinergic agents

Ethers of tropine or tropine derivatives

BENZTROPINE MESYLATE

| | | | | | | | | |
|-------|------------------------|---|----|----|--------|-------|----------|----|
| 5031T | Injection 2 mg in 2 mL | 5 | .. | .. | 103.59 | 34.20 | Cogentin | FK |
|-------|------------------------|---|----|----|--------|-------|----------|----|

Psycholeptics

Anxiolytics

Benzodiazepine derivatives

DIAZEPAM

| | | | | | | | | |
|-------|-------------------------|----|----|-------------------|-------|-------|---------------------------|----|
| 5071X | Tablet 2 mg | 50 | .. | .. | 7.72 | 8.81 | ^a Antenex 2 | AF |
| | | | | | | | ^a APO-Diazepam | TX |
| | | | | | | | ^a Ranzepam | RA |
| | | | | | | | ^a Valpam 2 | QA |
| | | | | ^B 0.82 | 8.54 | 8.81 | ^a Valium | RO |
| 5072Y | Tablet 5 mg | 50 | .. | .. | 7.85 | 8.94 | ^a Antenex 5 | AF |
| | | | | | | | ^a APO-Diazepam | TX |
| | | | | | | | ^a Diazepam-GA | GM |
| | | | | | | | ^a Ranzepam | RA |
| | | | | | | | ^a Valpam 5 | QA |
| | | | | ^B 0.85 | 8.70 | 8.94 | ^a Valium | RO |
| 5073B | Injection 10 mg in 2 mL | 5 | .. | .. | 12.29 | 13.38 | Hospira Pty Limited | HH |

OXAZEPAM

| | | | | | | | | |
|-------|--------------|----|----|-------------------|-------|------|---------------------------|----|
| 5192G | Tablet 15 mg | 25 | .. | .. | 7.49 | 8.58 | ^a Alepam 15 | AF |
| | | | | ^B 2.69 | 10.18 | 8.58 | ^a Serepax | QA |
| 5193H | Tablet 30 mg | 25 | .. | .. | 7.65 | 8.74 | ^a Alepam 30 | AF |
| | | | | | | | ^a APO-Oxazepam | TX |
| | | | | | | | ^a Murelax | FM |
| | | | | ^B 2.69 | 10.34 | 8.74 | ^a Serepax | QA |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price | Maximum | Brand Name and Manufacturer | | |
|--|---|-------------|-------------|-------------------|-----------------------|---|-----------------------------|---------------|----|
| | | | | | for Max. Qty \$ | Recordable Value for Safety Net \$ | | | |
| Hypnotics and sedatives | | | | | | | | | |
| <i>Benzodiazepine derivatives</i> | | | | | | | | | |
| NITRAZEPAM | | | | | | | | | |
| 5189D | Tablet 5 mg | 25 | .. | .. | 7.82 | 8.91 | ^a | Alodorm | AF |
| | | | | ^B 1.45 | 9.27 | 8.91 | ^a | Mogadon | VT |
| TEMAZEPAM | | | | | | | | | |
| 5221T | Tablet 10 mg | 25 | .. | .. | 7.64 | 8.73 | ^a | APO-Temazepam | TX |
| | | | | | | | ^a | Temaze | AF |
| | | | | ^B 1.44 | 9.08 | 8.73 | ^a | Temtabs | FM |
| | | | | | | | ^a | Normison | QA |

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer |
|------|---|-------------|-------------|---------|--|--|-----------------------------|
|------|---|-------------|-------------|---------|--|--|-----------------------------|

Respiratory system

Drugs for obstructive airway diseases

Adrenergics for systemic use

Alpha- and beta-adrenoceptor agonists

ADRENALINE

| | | | | | | | | |
|-------|-------------------------------------|---|----|----|-------|-------|----------------------------------|----|
| 5004J | Injection 1 mg in 1 mL (1 in 1,000) | 5 | .. | .. | 20.34 | 21.43 | Link Medical Products Pty Ltd | LM |
|-------|-------------------------------------|---|----|----|-------|-------|----------------------------------|----|

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer | |
|------|---|-------------|-------------|---------|--|--|-----------------------------|--|
|------|---|-------------|-------------|---------|--|--|-----------------------------|--|

Sensory organs

Ophthalmologicals

Antiinfectives

Antibiotics

CHLORAMPHENICOL

| | | | | | | | | |
|-------|-------------------------------------|----|----|----|-------|-------|---------------------------|----------|
| 5055C | Eye drops 5 mg per mL (0.5%), 10 mL | ‡1 | .. | .. | 11.00 | 12.09 | Chloromycetin Chlorsig | PF QA |
|-------|-------------------------------------|----|----|----|-------|-------|---------------------------|----------|

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Brand Name and Manufacturer | |
|------|---|-------------|-------------|---------|--|--|-----------------------------|--|
|------|---|-------------|-------------|---------|--|--|-----------------------------|--|

Various

All other therapeutic products

All other therapeutic products

Antidotes

NALOXONE HYDROCHLORIDE

| | | | | | | | | |
|-------|------------------------|---|----|----|-------|-------|--------------------|----|
| 5175J | Injection 2 mg in 5 mL | 1 | .. | .. | 43.49 | 34.20 | Naloxone Min-I-Jet | CS |
|-------|------------------------|---|----|----|-------|-------|--------------------|----|

All other non-therapeutic products

All other non-therapeutic products

Solvents and diluting agents, incl. irrigating solutions

SODIUM CHLORIDE

| | | | | | | | | |
|-------|-------------------------------------|---|----|----|-------|-------|-----------------------------|----|
| 5211G | Injection 9 mg per mL (0.9%), 10 mL | 5 | .. | .. | 16.29 | 17.38 | Pfizer Australia Pty Ltd | PF |
|-------|-------------------------------------|---|----|----|-------|-------|-----------------------------|----|

GENERIC/PROPRIETARY INDEX

A

| | |
|--|------------|
| <i>Abbccillin-V (QA)</i> | 28 |
| <i>Abbccillin-VK Filmstab (QA)</i> | 27 |
| <i>Aclor 125 (QA)</i> | 31 |
| <i>Aclor 250 (QA)</i> | 31 |
| ADRENALINE | 23, 43 |
| <i>Alepam 15 (AF)</i> | 41 |
| <i>Alepam 30 (AF)</i> | 41 |
| <i>Alodorm (AF)</i> | 42 |
| <i>Alphamox 125 (AF)</i> | 27 |
| <i>Alphamox 250 (AF)</i> | 26, 27 |
| <i>Alphamox 500 (AF)</i> | 26 |
| <i>Amoxil (GK)</i> | 19, 26, 27 |
| <i>Amoxil Forte (GK)</i> | 27 |
| AMOXYCILLIN | 19, 26 |
| <i>Amoxycillin generichealth 500 (GQ)</i> | 26 |
| <i>Amoxycillin Ranbaxy (RA)</i> | 26 |
| <i>Amoxycillin Sandoz (SZ)</i> | 26, 27 |
| AMOXYCILLIN with CLAVULANIC ACID | 28 |
| <i>Amoxycillin/ Clavulanic Acid 500/125 generichealth (GQ)</i> | 29 |
| <i>Amoxycillin/ Clavulanic Acid 875/125 generichealth (GQ)</i> | 29 |
| <i>Amoxycillin-GA (GM)</i> | 26 |
| AMPHOTERICIN | 20 |
| AMPICILLIN | 27 |
| <i>Anamorph (FM)</i> | 39 |
| <i>Anaprox 550 (RO)</i> | 37 |
| <i>Anginine Stabilised (QA)</i> | 23 |
| <i>Antenex 2 (AF)</i> | 41 |
| <i>Antenex 5 (AF)</i> | 41 |
| <i>APO- Paracetamol/Codeine 500/30 (TX)</i> | 38 |
| <i>APO-Amoxycillin (TX)</i> | 26 |
| <i>APO-Amoxycillin/ Clavulanic Acid 500/125 (TX)</i> | 29 |
| <i>APO-Cephalexin (TX)</i> | 30 |
| <i>APO-Diazepam (TX)</i> | 41 |
| <i>APO-Diclofenac (TX)</i> | 35 |
| <i>APO-Oxazepam (TX)</i> | 41 |
| <i>APO-Paracetamol (TX)</i> | 40 |
| <i>APO-Prochlorperazine (TX)</i> | 20 |
| <i>APO-Roxithromycin (TX)</i> | 32, 33 |
| <i>APO-Temazepam (TX)</i> | 42 |
| <i>APO-Tramadol (TX)</i> | 39 |
| <i>Arthrexin (AF)</i> | 35 |
| <i>Aspen Ampicyn (AS)</i> | 27 |
| ASPIRIN | 40 |
| ATROPINE | 20 |
| <i>Augmentin (GK)</i> | 29 |
| <i>Augmentin Duo (GK)</i> | 29 |
| <i>Augmentin Duo 400 (GK)</i> | 29 |
| <i>Augmentin Duo forte (GK)</i> | 29 |
| <i>Austrapen (LN)</i> | 27 |

B

| | |
|--|--------|
| <i>B. Braun Australia Pty Ltd (BR)</i> | 22 |
| <i>Bactrim (RO)</i> | 32 |
| <i>Bactrim DS (RO)</i> | 32 |
| <i>Baxter Healthcare Pty Ltd (BX)</i> | 22, 34 |
| <i>BenPen (CS)</i> | 27 |
| BENZATHINE BENZYL PENICILLIN | 27 |
| BENZTROPINE MESYLATE | 41 |

| | |
|--|--------|
| BENZYDAMINE HYDROCHLORIDE | 20 |
| BENZYL PENICILLIN | 27 |
| BETAMETHASONE ACETATE with BETAMETHASONE SODIUM PHOSPHATE | 25 |
| <i>Bgramin (GM)</i> | 27 |
| <i>Biaxig (AV)</i> | 32, 33 |
| <i>Bicillin L-A (AS)</i> | 27 |
| <i>Brufen (AB)</i> | 36 |

C

| | |
|---|--------|
| CARBAMAZEPINE | 41 |
| <i>Carbamazepine Sandoz (SZ)</i> | 41 |
| <i>Ceclor (AS)</i> | 31 |
| <i>Ceclor CD (AS)</i> | 31 |
| CEFACTOR | 31 |
| <i>Cefaclor Sandoz (SZ)</i> | 31 |
| <i>Cefaclor-GA (GN)</i> | 31 |
| <i>Cefalexin Sandoz (SZ)</i> | 30, 31 |
| CEFALOTIN | 30 |
| <i>Cefalotin Sandoz (SZ)</i> | 30 |
| CEFOTAXIME | 32 |
| <i>Cefotaxime Sandoz (SZ)</i> | 32 |
| CEFUROXIME AXETIL | 31 |
| <i>Celestone Chronodose (MK)</i> | 25 |
| <i>Cephabeil (BF)</i> | 30 |
| CEPHALEXIN | 30 |
| <i>Cephalexin generichealth (GQ)</i> | 30 |
| <i>Cephatrust 250 (MI)</i> | 30 |
| <i>Cephatrust 500 (MI)</i> | 30 |
| <i>Chem mart Amoxycillin (CH)</i> | 26, 27 |
| <i>Chem mart Amoxycillin and Clavulanic Acid (CH)</i> | 29 |
| <i>Chem mart Cefaclor (CH)</i> | 31 |
| <i>Chem mart Cefaclor CD (CH)</i> | 31 |
| <i>Chem mart Cephalexin (CH)</i> | 30, 31 |
| <i>Chem mart Diclofenac (CH)</i> | 35 |
| <i>Chem mart Doxycycline (CH)</i> | 26 |
| <i>Chem mart Paracetamol (CH)</i> | 40 |
| <i>Chem mart Piroxicam (CH)</i> | 36 |
| <i>Chem mart Roxithromycin (CH)</i> | 32, 33 |
| <i>Chem mart Tramadol (CH)</i> | 39 |
| CHLORAMPHENICOL | 44 |
| <i>Chloromycetin (PF)</i> | 44 |
| <i>Chlorsig (QA)</i> | 44 |
| <i>Cilamox (QA)</i> | 26, 27 |
| <i>Cilex (GM)</i> | 30, 31 |
| <i>Cilicaine (QA)</i> | 28 |
| <i>Cilicaine V (FM)</i> | 28 |
| <i>Cilicaine VK (FM)</i> | 27, 28 |
| <i>Cilopen VK (GM)</i> | 27, 28 |
| <i>Clamoxyl (AL)</i> | 29 |
| <i>Clamoxyl Duo (AL)</i> | 29 |
| <i>Clamoxyl Duo 400 (AL)</i> | 29 |
| <i>Clamoxyl Duo forte (AL)</i> | 29 |
| <i>Clavycillin 875/125 (CR)</i> | 29 |
| <i>Cleocin (FZ)</i> | 33 |
| CLINDAMYCIN | 33 |
| <i>Clonac 25 (QA)</i> | 35 |
| <i>Clonac 50 (QA)</i> | 35 |
| <i>Codalgin Forte (FM)</i> | 38 |
| <i>Codapane Forte (AL)</i> | 38 |
| CODEINE PHOSPHATE | 38 |

| | |
|---|----|
| CODEINE PHOSPHATE with PARACETAMOL | 38 |
| <i>Cogentin (FK)</i> | 41 |
| <i>Comfarol Forte (SZ)</i> | 38 |
| <i>Cortic-DS 1% (FM)</i> | 24 |
| <i>Crysanal (MD)</i> | 37 |
| <i>Curam (SZ)</i> | 29 |
| <i>Curam Duo (SZ)</i> | 29 |
| <i>Curam Duo 500/125 (SZ)</i> | 29 |
| <i>Curam Duo Forte 875/125 (SZ)</i> | 29 |

D

| | |
|--|----|
| <i>Dalacin C (PF)</i> | 33 |
| <i>DBL Metronidazole Intravenous Infusion (HH)</i> | 34 |
| <i>Depo-Medrol (PF)</i> | 25 |
| <i>Depo-Nisolone (FZ)</i> | 25 |
| DIAZEPAM | 41 |
| <i>Diazepam-GA (GM)</i> | 41 |
| <i>Diclocil (BQ)</i> | 28 |
| <i>Diclofenac Sandoz (SZ)</i> | 35 |
| DICLOFENAC SODIUM | 35 |
| <i>Diclofenac-GA (GM)</i> | 35 |
| DICLOXACILLIN | 28 |
| <i>Dicloxig (QA)</i> | 28 |
| <i>Difflam (IA)</i> | 20 |
| <i>Dilaudid (MF)</i> | 38 |
| <i>Distaph 250 (AF)</i> | 28 |
| <i>Distaph 500 (AF)</i> | 28 |
| <i>Dolaforte (CO)</i> | 38 |
| <i>Doryx (YN)</i> | 26 |
| <i>Douglas Cefaclor-CD (GM)</i> | 31 |
| <i>Doxsig (QA)</i> | 26 |
| <i>Doxy-100 (GM)</i> | 26 |
| DOXYCYCLINE | 26 |
| <i>Doxyhexal (SZ)</i> | 26 |
| <i>Doxylin 100 (AF)</i> | 26 |

E

| | |
|--------------------------------------|----|
| <i>E.E.S. 200 (LM)</i> | 32 |
| <i>E.E.S. 400 Filmtab (LM)</i> | 32 |
| <i>E.E.S. Granules (LM)</i> | 32 |
| <i>E-Mycin (AF)</i> | 32 |
| <i>E-Mycin 200 (AF)</i> | 32 |
| <i>E-Mycin 400 (AF)</i> | 32 |
| <i>Endone (QA)</i> | 39 |
| <i>Eryc (YN)</i> | 32 |
| <i>Erythrocin-I.V. (LM)</i> | 32 |
| ERYTHROMYCIN | 32 |
| ERYTHROMYCIN ETHYL SUCCINATE | 32 |
| ERYTHROMYCIN LACTOBIONATE | 32 |

F

| | |
|---|--------|
| <i>Fawns and McAllan Proprietary Limited (FM)</i> | 38 |
| <i>Febridol (GM)</i> | 40 |
| <i>Feldene (PF)</i> | 36 |
| <i>Feldene-D (PF)</i> | 36 |
| <i>Fenac (AF)</i> | 35 |
| <i>Fenac 25 (AF)</i> | 35 |
| <i>Flagyl (SW)</i> | 33, 34 |
| <i>Flagyl S (SW)</i> | 34 |
| <i>Flopen (AS)</i> | 28 |
| <i>Flubiclox (TS)</i> | 28 |
| <i>Flucil (AS)</i> | 28 |

| | |
|--|----|
| <i>Flucil (LN)</i> | 28 |
| FLUCLOXACILLIN | 28 |
| <i>Fresenius Kabi Australia Pty Limited (PK)</i> | 22 |
| <i>Fungilin (QA)</i> | 20 |

G

| | |
|---|--------|
| <i>GA Tramadol 50mg (GM)</i> | 39 |
| <i>GA-Amclav 500/125 (GM)</i> | 29 |
| <i>GA-Amclav Forte 875/125 (GM)</i> | 29 |
| <i>Generic Health Pty Ltd (GQ)</i> | 40 |
| <i>GenRx Amoxicillin (GX)</i> | 26, 27 |
| <i>GenRx Amoxicillin and Clavulanic Acid (GX)</i> | 29 |
| <i>GenRx Cefaclor (GX)</i> | 31 |
| <i>GenRx Cefaclor CD (GX)</i> | 31 |
| <i>GenRx Cephalexin (GX)</i> | 30, 31 |
| <i>GenRx Doxycycline (GX)</i> | 26 |
| <i>GenRx Piroxicam (GX)</i> | 36 |
| <i>GenRx Tramadol (GX)</i> | 39 |
| <i>GlucaGen Hypokit (NO)</i> | 25 |
| GLUCAGON HYDROCHLORIDE | 25 |
| GLUCOSE | 22 |
| GLYCERYL TRINITRATE | 23 |

H

| | |
|---------------------------------------|----------------------------|
| <i>Hospira Pty Limited (HH)</i> | 21, 28, 30, 32, 33, 39, 41 |
| HYDROCORTISONE ACETATE | 24 |
| HYDROCORTISONE SODIUM SUCCINATE | 25 |
| HYDROMORPHONE HYDROCHLORIDE | 38 |

I

| | |
|------------------------------|--------|
| <i>Ialex (LN)</i> | 30, 31 |
| <i>Ibilex 125 (AF)</i> | 30 |
| <i>Ibilex 250 (AF)</i> | 30, 31 |
| <i>Ibilex 500 (AF)</i> | 30 |
| <i>Ibimicyn (TS)</i> | 27 |
| IBUPROFEN | 36 |
| <i>Indocid (AS)</i> | 35 |
| INDOMETHACIN | 35 |
| <i>Inza 250 (AF)</i> | 36 |
| <i>Inza 500 (AF)</i> | 36 |

K

| | |
|----------------------------------|--------|
| <i>Karlors CD (LN)</i> | 31 |
| <i>Keflex (AS)</i> | 30, 31 |
| <i>Keflin Neutral (AS)</i> | 30 |
| <i>Keflor (AF)</i> | 31 |
| <i>Keflor CD (AF)</i> | 31 |
| <i>Kenacort-A10 (QA)</i> | 25 |
| KETOPROFEN | 36 |

L

| | |
|---|--------|
| LIGNOCAINE HYDROCHLORIDE | 23 |
| <i>Lincocin (PF)</i> | 33 |
| LINCOMYCIN | 33 |
| <i>Link Medical Products Pty Ltd (LM)</i> | 23, 43 |
| <i>Lodam 50 (ZP)</i> | 39 |
| <i>LPV (VT)</i> | 27, 28 |
| <i>Lycinate (FM)</i> | 23 |

M

| | |
|--|--------|
| <i>Maxamox (SZ)</i> | 27 |
| <i>Maxolon (VT)</i> | 20 |
| <i>Mayne Pharma Doxycycline (YT)</i> | 26 |
| <i>Mayne Pharma Erythromycin (YT)</i> | 32 |
| METHYLPREDNISOLONE ACETATE..... | 25 |
| METOCLOPRAMIDE HYDROCHLORIDE..... | 20 |
| <i>Metrogyl 200 (AF)</i> | 33 |
| <i>Metrogyl 400 (AF)</i> | 34 |
| METRONIDAZOLE..... | 33, 34 |
| METRONIDAZOLE BENZOATE..... | 34 |
| <i>Metronidazole Sandoz (SZ)</i> | 34 |
| <i>Metronide 200 (AV)</i> | 33 |
| <i>Metronide 400 (AV)</i> | 34 |
| <i>Mobilis 10 (AF)</i> | 36 |
| <i>Mobilis 20 (AF)</i> | 36 |
| <i>Mobilis D-10 (AF)</i> | 36 |
| <i>Mobilis D-20 (AF)</i> | 36 |
| <i>Mogadon (VT)</i> | 42 |
| MORPHINE HYDROCHLORIDE..... | 38 |
| MORPHINE SULFATE..... | 38, 39 |
| <i>Moxiclav Duo 500/125 (QA)</i> | 29 |
| <i>Moxiclav Duo Forte 875/125 (QA)</i> | 29 |
| <i>Murelax (FM)</i> | 41 |
| <i>Mycostatin (FM)</i> | 20 |

N

| | |
|--------------------------------------|--------|
| NALOXONE HYDROCHLORIDE..... | 45 |
| <i>Naloxone Min-I-Jet (CS)</i> | 45 |
| <i>Naprosyn (RO)</i> | 36 |
| <i>Naprosyn SR1000 (RO)</i> | 36 |
| <i>Naprosyn SR750 (RO)</i> | 36 |
| NAPROXEN..... | 36 |
| NAPROXEN SODIUM..... | 37 |
| <i>Nilstat (QA)</i> | 20, 21 |
| NITRAZEPAM..... | 42 |
| <i>Normison (QA)</i> | 42 |
| NYSTATIN..... | 20, 21 |

O

| | |
|--|----|
| <i>Ordine 10 (MF)</i> | 38 |
| <i>Ordine 2 (MF)</i> | 38 |
| <i>Ordine 5 (MF)</i> | 38 |
| <i>Orudis (SW)</i> | 36 |
| <i>Orudis SR 200 (SW)</i> | 36 |
| <i>Oruvail SR (AV)</i> | 36 |
| OXAZEPAM..... | 41 |
| OXYCODONE..... | 39 |
| OXYCODONE HYDROCHLORIDE..... | 39 |
| <i>OxyNorm (MF)</i> | 39 |
| <i>OxyNorm Liquid 5mg/5mL (MF)</i> | 39 |
| <i>Ozcef (RA)</i> | 31 |

P

| | |
|--|------------|
| <i>Panadeine Forte (SW)</i> | 38 |
| <i>Panamax (SW)</i> | 40 |
| <i>Panamax 240 Elixir (SW)</i> | 40 |
| PARACETAMOL..... | 40 |
| <i>Paracetamol Sandoz (SZ)</i> | 40 |
| <i>Paralgin (FM)</i> | 40 |
| <i>Pfizer Australia Pty Ltd (PF)</i> | 20, 23, 45 |

| | |
|--|----|
| <i>Pharmacor Cephalexin 250 (CR)</i> | 30 |
| <i>Pharmacor Cephalexin 500 (CR)</i> | 30 |
| <i>Pharmacy Choice Paracetamol (YM)</i> | 40 |
| <i>Phenoxyethyl- penicillin-AFT (AE)</i> | 28 |
| PHENOXYMETHYLPENICILLIN..... | 27 |
| PIROXICAM..... | 35 |
| <i>Pramin (AF)</i> | 20 |
| PROCAINE PENICILLIN..... | 28 |
| <i>ProCalm (QA)</i> | 20 |
| PROCHLORPERAZINE..... | 20 |
| <i>Prochlorperazine-GA (GM)</i> | 20 |
| <i>Prodeine Forte (AV)</i> | 38 |
| <i>Proladone (PL)</i> | 39 |
| PROMETHAZINE HYDROCHLORIDE..... | 21 |
| <i>Proxen SR 1000 (MD)</i> | 36 |
| <i>Proxen SR 750 (MD)</i> | 36 |

R

| | |
|------------------------------------|--------|
| <i>Rancef (RA)</i> | 30 |
| <i>Ranmoxy (RA)</i> | 27 |
| <i>Ranzepam (RA)</i> | 41 |
| <i>Resprim Forte (AF)</i> | 32 |
| <i>Roxar 150 (QA)</i> | 32 |
| <i>Roxar 300 (QA)</i> | 33 |
| <i>Roxide (SZ)</i> | 32, 33 |
| <i>Roximycin (AF)</i> | 32, 33 |
| ROXITHROMYCIN..... | 32 |
| <i>Roxithromycin-GA (GM)</i> | 32, 33 |
| <i>Rulide (SW)</i> | 33 |
| <i>Rulide D (SW)</i> | 32 |

S

| | |
|-----------------------------------|--------|
| <i>Seprin (QA)</i> | 32 |
| <i>Seprin Forte (QA)</i> | 32 |
| <i>Serepax (QA)</i> | 41 |
| <i>Sigmacort (QA)</i> | 24 |
| SODIUM CHLORIDE..... | 22, 45 |
| SODIUM CHLORIDE with GLUCOSE..... | 22 |
| <i>Solprin (RC)</i> | 40 |
| <i>Solu-Cortef (PF)</i> | 25 |
| <i>Staphylex 250 (AF)</i> | 28 |
| <i>Staphylex 500 (AF)</i> | 28 |
| <i>Stemetil (SW)</i> | 20 |
| <i>Stemzine (AV)</i> | 20 |

T

| | |
|--|--------|
| <i>Tegretol 100 (NV)</i> | 41 |
| <i>Tegretol 200 (NV)</i> | 41 |
| <i>Tegretol CR 200 (NV)</i> | 41 |
| <i>Tegretol CR 400 (NV)</i> | 41 |
| <i>Tegretol Liquid (NV)</i> | 41 |
| <i>Temaze (AF)</i> | 42 |
| TEMAZEPAM..... | 42 |
| <i>Temtabs (FM)</i> | 42 |
| <i>Teril (AF)</i> | 41 |
| <i>Terry White Chemists Amoxicillin (TW)</i> | 26, 27 |
| <i>Terry White Chemists Amoxicillin and Clavulanic Acid (TW)</i> | 29 |
| <i>Terry White Chemists Cefaclor (TW)</i> | 31 |
| <i>Terry White Chemists Cefaclor CD (TW)</i> | 31 |
| <i>Terry White Chemists Cephalexin (TW)</i> | 30, 31 |
| <i>Terry White Chemists Diclofenac (TW)</i> | 35 |
| <i>Terry White Chemists Doxycycline (TW)</i> | 26 |

| | |
|--|--------|
| <i>Terry White Chemists Paracetamol (TW)</i> | 40, 41 |
| <i>Terry White Chemists Piroxicam (TW)</i> | 36 |
| <i>Terry White Chemists Roxithromycin (TW)</i> | 32, 33 |
| <i>Terry White Chemists Tramadol (TW)</i> | 39 |
| TICARCILLIN with CLAVULANIC ACID | 29 |
| <i>Timentin (GK)</i> | 29 |
| TRAMADOL HYDROCHLORIDE | 39, 40 |
| <i>Tramadol Sandoz (SZ)</i> | 39 |
| <i>Tramahexal (SZ)</i> | 40 |
| <i>Tramal (CS)</i> | 40 |
| <i>Tramal 100 (CS)</i> | 40 |
| <i>Tramedo (AF)</i> | 39 |
| TRIAMCINOLONE ACETONIDE | 25 |
| TRIMETHOPRIM with SULFAMETHOXAZOLE | 32 |

V

| | |
|--------------------------|----|
| <i>Valium (RO)</i> | 41 |
|--------------------------|----|

| | |
|---|----|
| <i>Valpam 2 (QA)</i> | 41 |
| <i>Valpam 5 (QA)</i> | 41 |
| <i>Vancocin CP (AS)</i> | 33 |
| VANCOMYCIN | 33 |
| <i>Vancomycin Alphapharm (AF)</i> | 33 |
| <i>Vancomycin Sandoz (SZ)</i> | 33 |
| <i>Voltaren 100 (NV)</i> | 35 |
| <i>Voltaren 25 (NV)</i> | 35 |
| <i>Voltaren 50 (NV)</i> | 35 |
| <i>Vycin IV (WQ)</i> | 33 |

Z

| | |
|--------------------------|----|
| <i>Zinnat (GK)</i> | 31 |
| <i>Zydol (QA)</i> | 39 |